MECHANISM OF BLOCK AND BEHAVIORAL EFFECTS OF THE N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS MEMANTINE AND KETAMINE by Kotermanski, Shawn Edward
 MECHANISM OF BLOCK AND BEHAVIORAL EFFECTS OF THE N-METHYL-D-
ASPARTATE RECEPTOR ANTAGONISTS MEMANTINE AND KETAMINE 
 
 
 
 
 
 
 
by 
Shawn Edward Kotermanski  
B.S. in Neuroscience, University of Pittsburgh, 2001 
 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
Arts and Sciences in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2008 
 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF ARTS AND SCIENCES 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Shawn Edward Kotermanski 
 
 
 
It was defended on 
November 24, 2008 
and approved by 
Stephen D. Meriney, PhD 
Bita Moghaddam, PhD 
Edda Thiels, PhD 
Stefano Vicini, PhD 
David C. Wood, PhD 
Jon W. Johnson, PhD 
Dissertation Director 
 ii 
MECHANISM OF BLOCK AND BEHAVIORAL EFFECTS OF THE N-METHYL-D-
ASPARTATE RECEPTOR ANTAGONISTS MEMANTINE AND KETAMINE 
 
Shawn Kotermanski, PhD 
University of Pittsburgh, 2008
 
Pharmacological inhibition of NMDA receptor activity by ketamine is accompanied by 
pyschotomimetic side-effects; however, the Alzheimer’s disease therapeutic memantine blocks 
NMDA receptor activity without debilitating side-effects.  This dissertation provides 
electrophysiological and behavioral characterizations of these two NMDA receptor antagonists 
in an attempt to understand the unique therapeutic utility of memantine.  The following work 
explores memantine and ketamine inhibition at NMDA receptors, their main site of action, with a 
focus on the mechanism of inhibition and receptor subtype selectivity in physiologically relevant 
conditions.  This research shows NMDA receptors possess a second binding site at which 
memantine, but not ketamine, can inhibit activity.  The research also shows the dramatic effect 
physiological concentrations of magnesium has on the ability of these drugs to inhibit NMDA 
receptor activity.  Behavioral and cognitive effects of memantine and ketamine are also assessed 
and compared directly in rat.  The effects of memantine and ketamine in rat were found to be 
similar at the low doses tested and more divergent as dose increased.  Furthermore, memantine’s 
effects appeared to be more pronounced and longer-lasting than those of ketamine.  These 
findings demonstrate the importance of considering the physiological environment in which a 
drug acts, as well as the principles of drug action, when examining the effects of a drug on 
central nervous system activity. 
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1.0  BACKGROUND AND INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Most excitatory synaptic communication occurring within the vertebrate central nervous system 
is mediated by the glutamate receptor family of ligand-gated ion channels.  N-methyl-D-aspartate 
(NMDA) receptors are a subtype of glutamate receptors that possess unique properties that allow 
them to contribute to a variety of physiological (development, learning and memory) and 
pathological (ischemic cell death, many neurodegenerative disorders) processes (Bliss and 
Collingridge, 1993; Dingledine et al., 1999; Olney, 2003).  Alteration of the ability of NMDA 
receptors to transmit information reliably can result in behavioral and cognitive disturbances 
(Lodge et al., 2002). 
Pharmacological modulation of NMDA receptor-mediated neurotransmission has 
generally been accompanied by debilitating psychotomimetic side-effects (Palmer, 2001; Lipton, 
2004b).  While not widely used clinically, some NMDA receptor antagonists (such as ketamine 
and phencyclidine (PCP) have been crucial in furthering our understanding of the underlying 
pathologies of schizophrenia.  Ketamine, as well as PCP, reliably reproduces positive 
(hallucinations and delusions), negative (decreased affect), and disorganizational (thought 
disorder) symptoms of schizophrenia in healthy human adults as well as worsening symptoms in 
already afflicted individuals (Krystal et al., 1999b).  Memantine, another NMDA receptor 
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antagonist, with a mechanism of inhibition comparable to that of ketamine, lacks 
psychotomimetic side-effects and also has shown therapeutic utility by decreasing the cognitive 
decline associated with late stages of moderate-to-severe Alzheimer’s disease.  The goal of this 
work is to evaluate the mechanism of action and behavioral effects of NMDA receptor inhibition 
by memantine and ketamine to improve our understanding of the therapeutic potential NMDA 
receptor antagonism may hold. 
1.2 NMDA RECEPTOR PROPERTIES 
1.2.1 Gene products and expression patterns 
NMDA receptor subunit proteins are produced from seven different genes that encode three 
subunit families: NR1, NR2, and NR3 (Moriyoshi et al., 1991; Monyer et al., 1992; Ishii et al., 
1993; Monyer et al., 1994; Ciabarra et al., 1995; Sucher et al., 1995; Dingledine et al., 1999; 
Chatterton et al., 2002; Matsuda et al., 2003).  One gene (GRIN1) encodes the NR1 subunit, with 
eight splice variants produced by alternative splicing (Zukin and Bennett, 1995).  Four genes 
(GRIN2A-D) produce distinct NR2 subunits, NR2A-D.  Functional NMDA receptors require the 
presence of NR1 and at least one of the four NR2 subtypes.  NR3 subunits are the products of 
two genes (GRIN3A-B) and have been labeled NR3A and NR3B.  Incorporation of NR3 subunits 
modifies NMDA receptor functioning (Das et al., 1998; Chatterton et al., 2002; Matsuda et al., 
2002; Matsuda et al., 2003; Smothers and Woodward, 2007).  Electrophysiological studies 
(Chatterton et al., 2002; Matsuda et al., 2002; Matsuda et al., 2003; Smothers and Woodward, 
2007) suggest that NR3 subunits can form excitatory glycine receptors when co-expressed with 
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NR1, although little is known about the physiological relevance of NR3 subunits in nervous 
system functioning. 
NR1 mRNA expression develops along a caudal to rostral gradient.  Regional specificity 
of NR1 splice variants is present at birth and remains fixed through adulthood, with the only 
developmental change being shifts in the density of the respective splice variants (Laurie and 
Seeburg, 1994; Laurie et al., 1995).  NR2 mRNA expression is both developmentally and 
regionally regulated (Monyer et al., 1994).  Prenatally, NR2B and NR2D subunits predominate, 
with NR2D expression levels peaking about one week after birth and NR2B levels peaking about 
three weeks postnatally.  NR2A and NR2C subunits begin to appear near birth and increase to 
peak levels around the third postnatal week.  After reaching peak expression, all NR2 and NR1 
subunit expression decreases to adult levels (Laurie and Seeburg, 1994).  NR1 subunits are found 
throughout the adult central nervous system (CNS); however, the expression of NR2 subtypes is 
more regionally restricted.  NMDA receptor subunit protein expression for the most part overlaps 
expression patterns reported for subunit mRNAs (Petralia et al., 1994a; Petralia et al., 1994b; 
Portera-Cailliau et al., 1996; Wenzel et al., 1996).  The NR2A subunit is the most widely 
expressed subtype in the adult brain.  The NR2B subunit is expressed mostly in the adult cortex 
and the hippocampus, and NR2C is heavily expressed in the cerebellum.  NR2D is moderately 
expressed in the adult midbrain and brainstem, with lower levels in the cortex.  Expression of 
NR2 subunits is neuron subtype-specific within certain brain regions.  In the hippocampus, for 
example, NR2A and NR2B are highly expressed in pyramidal neurons whereas NR2D is found 
in interneurons (Monyer et al., 1994).  
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1.2.2 NMDA receptor structure   
A crystal structure of the NMDA receptor does not exist, most likely due to the difficulty in 
crystallizing membrane proteins, especially one as complex as the NMDA receptor.  Therefore, 
the exact structure and location of critical determinants of receptor function are not fully 
understood.  However, evidence exists that sheds light on the structure of NMDA receptors as 
well as the roles specific amino acids play in receptor functioning. 
1.2.2.1 Subunit topology 
The subunit topology of ionotropic glutamate receptors is conserved among NMDA, α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainite receptors (Dingledine et al., 
1999).  The protein structure of an NMDA receptor subunit begins at the extracellular amino-
terminal (N-terminal) end, contains three transmembrane regions (M1, M3, and M4) and a 
reentrant loop (M2) between transmembrane region M1 and M3, and ends with an intracellular 
carboxyl terminal tail (C-terminal) (Figure 1).   
NMDA receptors contain a region between the N-terminal domain and M1 called S1, 
which, along with the extracellular linker region located between M3 and M4 (S2), forms the 
agonist binding domain (ABD).  The reentrant loop formed by the M2 region lines the narrowest 
portion of the pore of NMDA receptors and creates the selectivity filter that allows the passage 
of specific ions through activated receptors.  The N-site (named for the asparagine residue 
located near the apex of the M2 loop) of the M2 region is critical for two unique NMDA receptor 
properties, calcium (Ca2+) permeation and block by endogenous extracellular magnesium 
(Mg2+o) (Burnashev et al., 1992; Kuner et al., 1996; Wollmuth et al., 1996; Wollmuth et al., 
1998).  The N-site of NR1 subunits strongly regulates Ca2+ permeability but is less involved in 
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mediating block by Mg2+o (Burnashev et al., 1992; Wollmuth et al., 1996; Wollmuth et al., 
1998).  The N + 1-site (an asparagine next to the N-site towards the C-terminal end), of NR2 
subunits has been shown to have a greater involvement in mediating block by Mg2+o than 
regulating Ca2+ permeability (Burnashev et al., 1992; Wollmuth et al., 1996; Wollmuth et al., 
1998).  Along with forming the binding site for Mg2+, the N-site is also involved in the binding 
of other NMDA receptor channel blockers (Dingledine et al., 1999; Kashiwagi et al., 2002).  The 
intracellular C-terminal region of NMDA receptor subunits contains sites that modulate NMDA 
receptor function, such as phosphorylation sites (Tingley et al., 1997) and sites for cytoskeletal, 
as well as cytoskeletal linker proteins (Wyszynski et al., 1997; Ehlers et al., 1998; Lei et al., 
2001).   
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Figure 1.  Topology and transmembrane structure of the NR1 and NR2 subunits of NMDA 
receptors.  Although four subunits are likely required for a functional receptor, only two subunits 
are shown here for clarity.  N and C designate the extracellular N-terminal and intracellular C-
terminal ends of the protein, respectively.  The three transmembrane regions (M1, M3, and M4) 
and the re-entrant pore loop (M2) are portrayed as black rounded cylinders.  Residues critical in 
regulating ion permeability and open-channel block by Mg2+o as well as many channel blockers, 
such as memantine and ketamine, are located near the apex of the M2 region.  The ligand 
binding pockets are depicted as the thick black lines shown N-terminal to M1 (S1) and on the 
M3 – M4 linker (S2).  The binding of glycine (Gly) to the NR1 subunit and glutamate (Glu) to 
the NR2 subunit are also portrayed.  
 
 
1.2.2.2 Stoichiometry 
The number of NMDA receptor subunits in functional receptors is not known with certainty.  
Most results suggest that two NR1 and two NR2 NMDA receptor subunits form a tetrameric 
receptor complex (Clements and Westbrook, 1991; Laube et al., 1998; Schorge and Colquhoun, 
2003).  The arrangement of NR1 and NR2 subunits around the channel pore is also unknown.  
There is evidence that a single NMDA receptor can contain two different NR2 subunits along 
with NR1 subunits (Sheng et al., 1994; Chazot and Stephenson, 1997; Dunah et al., 1998).  The 
incorporation of multiple NR2 subtypes will result in channel properties distinct from those of 
channels formed by NR1 subunits and one type of NR2 subunit (Wafford et al., 1993; 
Brimecombe et al., 1997; Vicini et al., 1998; Tovar and Westbrook, 1999; Cheffings and 
Colquhoun, 2000; Brickley et al., 2003). 
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1.2.3 NMDA receptor function 
NMDA receptors possess distinctive properties that allow them to play a unique role in 
excitatory synaptic transmission within the CNS (Dingledine et al., 1999).  Among these 
properties are the requirement of binding by two agonists, glutamate and glycine, for channel 
activation and ion flux.  Once activated, NMDA receptors allow for the permeation of Ca2+ into 
neurons.  Intracellular Ca2+ acts as an important signaling molecule inside neurons where it can 
activate intracellular signal transduction cascades that have wide-ranging and diverse effects on 
neuronal connections and viability.  A third unique property, use-dependent block by 
endogenous Mg2+o, regulates the flow of Ca2+ through NMDA receptors. 
1.2.3.1 Channel activation 
Ionotropic glutamate receptor activation requires binding of ligands.  The ABD is a clamshell-
like structure comprised of the S1 and S2 regions of a subunit.  Research on AMPA (Armstrong 
and Gouaux, 2000; Furukawa and Gouaux, 2003) and kainate receptors (Armstrong et al., 1998) 
suggests that the binding of ligand (agonist or antagonist) to the ABD results in closure of the 
S1S2 clamshell, which translates into movement of downstream portions of the receptor and 
channel opening.  The binding of agonists or antagonists results in different degrees of clamshell 
closure that translates to the movement of the S1 and S2 domains relative to the rest of the 
receptor complex.  Agonist binding results in clamshell closure to a degree that leads to 
sufficient tension on the pore-forming region to cause channel opening and allow ion flow.   
Based on the conservation of topology among glutamate receptors, it is reasonable to 
assume that NMDA receptor activation occurs in a similar manner.  The S1S2 complex of the 
NR1 NMDA receptor subunit binds the co-agonist glycine (Kuryatov et al., 1994; Hirai et al., 
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1996; Furukawa and Gouaux, 2003), and the corresponding site on NR2 binds the co-agonist 
glutamate (Laube et al., 1997; Anson et al., 1998; Lummis et al., 2002).  It is likely that four 
molecules of agonist (two glutamate and two glycine) are required for channel activation.  
Physiologically, aspartate and D-serine may also contribute to NMDA receptor activation by 
binding to the glutamate and glycine sites, respectively (Patneau and Mayer, 1990; Priestley et 
al., 1995; Schell et al., 1995). 
1.2.3.2 Ion permeation 
Activated NMDA receptors exhibit nearly equal permeability to the monovalent cations sodium 
(Na+), potassium (K+), and the less physiologically relevent cation cesium (Cs+) (Dingledine et 
al., 1999).  NMDA receptors are also highly permeable to the divalent cation Ca2+ (Burnashev et 
al., 1995).  The influx of cations through activated NMDA receptor channels results in 
depolarization of the corresponding neuron.  The varied and potentially deleterious effects of 
Ca2+ influx through NMDA receptors requires tight regulation of NMDA receptor-mediated 
transmission. 
1.2.3.3 Block by endogenous Mg2+o 
The binding of agonist and channel opening is not sufficient to allow ion flow through NMDA 
receptors.  Endogenous Mg2+o enters the pore of activated NMDA receptors, binds near the N-
site, and blocks the flow of ions through the channel at membrane voltages near rest (Burnashev 
et al., 1992; Kuner et al., 1996).  Mg2+o inhibition of NMDA receptors limits the influx of Ca2+ 
through activated receptors, preventing in physiological situations, the accumulation of 
intracellular Ca2+ to toxic levels.   
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The extent of Mg2+o inhibition of NMDA receptors is highly dependent on membrane 
voltage and subunit composition (Ascher and Nowak, 1988; Monyer et al., 1994; Momiyama et 
al., 1996; Dingledine et al., 1999).  At voltages near rest, physiological concentrations of Mg2+o 
inhibit a majority of NMDA receptor-mediated neurotransmission.  Membrane depolarization 
that results from the activation of non-NMDA glutamate receptors is necessary to reduce Mg2+o 
inhibition of NMDA receptors and allow the flow of ions through activated channels.  The type 
of NR2 subunit incorporated into the receptor strongly affects the degree of Mg2+o inhibition 
(Monyer et al., 1994; Momiyama et al., 1996).  Receptors composed of NR1 with NR2A and/or 
NR2B subunits are more strongly inhibited by Mg2+o than receptors that contain NR1 with NR2C 
and/or NR2D subunits. 
1.2.4 NMDA receptor pharmacology 
Many drugs exist that modulate NMDA receptor function, and most drugs decrease NMDA 
receptor activity.  Effective NMDA receptor inhibitors must be capable of preventing 
overactivity while preserving physiological levels of activity.  Two possibilities for inhibiting 
overactive NMDA receptors are competitive binding by antagonists and blocking the pore of 
activated receptors.  These two mechanisms of inhibition are associated with various advantages 
and disadvantages.     
1.2.4.1 Competitive antagonists 
Competitive antagonists of NMDA receptors work by binding at the agonist binding site.  The 
binding of antagonist to the agonist binding site prevents the conformational changes of the 
receptor necessary for channel opening.  The requirement of two different agonists for channel 
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activation offers two distinct sites at which competitive antagonists can act, the glycine binding 
site on the NR1 subunit and the glutamate binding site on the NR2 subunit.  Kynurenic acid 
derivatives, such as 5, 7-dichlorokynurenic acid (5, 7-DCK), are examples of competitive 
antagonists at the glycine site of NMDA receptors.  Phosphono derivatives of short-chain amino 
acids, such as 2-amino-5 phosphonopentanoic acid (AP5) and 2-amino-7 phosphonopentanoic 
acid (AP7), are examples of competitive antagonists at the glutamate site (Priestley et al., 1995; 
Dingledine et al., 1999).   
Competitive antagonists, especially at the glycine site, offer a way to inhibit the 
functioning of all NMDA receptors, because NR1 subunits are required for functional receptors.  
Competitive antagonists that bind at the glutamate site, potentially could allow for subunit-
specific inhibition of NMDA receptors; however, many glutamate site antagonists are not NR2 
subtype selective (Lodge et al., 2002). 
Inhibition by competitive antagonists is compromised in cases where a high 
concentration of agonist is present.  This effect is useful in preserving NMDA receptor-mediated 
synaptic transmission where high concentrations (~1 mM) of glutamate are released that can 
outcompete the antagonist for binding (Lodge et al., 2002). 
1.2.4.2 Channel blockers 
NMDA receptor antagonism by channel blockers is use-dependent, meaning that channel 
activation is required for these compounds to reach their binding site and exert their effects.  The 
N-site of NMDA receptors contributes to the binding site of several NMDA receptor channel 
blockers, including Mg2+o (Kashiwagi et al., 2002).  NMDA receptor inhibition by channel 
blockers is voltage-dependent, since their binding site is located within the membrane voltage 
field.  Voltage-dependent inhibition results in a decrease in a channel blocker’s ability to inhibit 
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NMDA receptor activity as membrane voltage depolarizes (MacDonald et al., 1987; MacDonald 
et al., 1991; Parsons et al., 1993; Parsons et al., 1995; Parsons et al., 1996; Blanpied et al., 1997; 
Aracava et al., 2005; Wrighton et al., 2008). 
A channel blocker can either prevent the closing of the channel while bound, or it can 
allow for channel closure around the bound blocker.  The differential effects of blockers on 
channel gating have led to the classification of channel blocking drugs as either sequential (foot-
in-the-door) blockers or trapping blockers, respectively. 
Sequential channel blockers are not unique to NMDA receptors and have been described 
for other ligand-gated ion channels (Neher and Steinbach, 1978).  The binding of a sequential 
channel blocker within the channel of activated receptors inhibits not only ion flow but also 
channel closure (Benveniste and Mayer, 1995; Antonov and Johnson, 1996).  A representative 
NMDA receptor sequential channel blocker is 9-aminoacridine (9-AA).  The mechanism 
responsible for stabilizing the open state of NMDA receptor channels while sequential blockers 
are bound is not completely understood.   
Trapping channel blockers bind within the channel of activated NMDA receptors and 
allow subsequent channel closure and dissociation of agonists, an effect that traps the drug 
within the pore of the receptor.  The rebinding of agonist and channel activation allows 
unbinding of the trapped blocker and its escape from the open channel (Huettner and Bean, 1988; 
Lerma et al., 1991; MacDonald et al., 1991; Parsons et al., 1993; Parsons et al., 1995; Parsons et 
al., 1996; Blanpied et al., 1997; Chen and Lipton, 1997; Sobolevsky and Koshelev, 1998; 
Sobolevsky et al., 1998; Mealing et al., 1999; Sobolevsky, 1999; Mealing et al., 2001; Kashiwagi 
et al., 2002; Bolshakov et al., 2003; Wrighton et al., 2008).  There are differences in the degree 
to which trapping blockers remain bound to closed channels.  Full trapping channel blockers 
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(such as the dissociative anesthetics ketamine and PCP) are compounds that, once trapped within 
closed NMDA receptors, cannot be released until subsequent channel opening allows escape 
back to the extracellular environment (Huettner and Bean, 1988; Lerma et al., 1991; Mealing et 
al., 1999; Mealing et al., 2001; Bolshakov et al., 2003).  Partial trapping channel blockers (such 
as the amino-adamantane derivative memantine) are capable of dissociating from a fraction of 
NMDA receptors before subsequent channel activation allows open channel escape (Blanpied et 
al., 1997; Chen and Lipton, 1997; Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; 
Mealing et al., 1999; Mealing et al., 2001; Bolshakov et al., 2003).  The underlying mechanism 
through which partial trapping channel blockers prevent being trapped is unknown. 
1.3 NMDA RECEPTOR ROLE IN PHYSIOLOGY AND PATHOLOGY 
1.3.1 NMDA receptor role in synaptic transmission 
NMDA receptor-mediated neurotransmission is tightly regulated.  NMDA receptors are 
coincidence detectors because of the requirement of presynaptic glutamate release and 
postsynaptic depolarization for channel activation and Mg2+o unblock to occur (Collingridge et 
al., 1988; McBain and Mayer, 1994; Albensi, 2007).  Postsynaptic depolarization typically arises 
from activation of other members of the glutamate receptor family, mainly AMPA receptors. 
1.3.1.1 Learning and memory 
Alteration in the strength of synaptic connections is believed to be a biophysical mechanism 
underlying learning and memory.  Changes in the strength of a synapse can be expressed as 
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either an increase or a decrease in the ability of a synapse to transmit information.  A long-lasting 
increase in the efficacy of a synapse is termed long-term potentiation (LTP) and a long-lasting 
decrease long-term depression (LTD) (Bliss and Collingridge, 1993; Rison and Stanton, 1995; 
Bear and Abraham, 1996; Riedel et al., 2003).  NMDA receptor activation has been shown to be 
critical in the expression of many forms of LTP and LTD at excitatory synapses (Malenka and 
Bear, 2004).   
For LTP induction, the intensity of postsynaptic activity must be strong enough to initiate 
the cascade of events that will strengthen the connection between the pre- and post-synaptic 
neuron.  Cooperativity, associativity, and input-specificity are three properties commonly found 
to be associated with LTP.  Cooperativity refers to the convergence and spatial/temporal pairing 
of signals that arise from many fibers.  Each signal alone is not intense enough to yield LTP; 
however, the combined activity of all the fibers converging on a postsynaptic site can surpass the 
threshold of signal strength required to result in LTP.  The ability of a weak signal to be 
potentiated, if its activity is paired with a strong stimulus at a separate but connected site, is 
called associativity.  Input-specificity, which is not a universal property of LTP, refers to the 
expression of LTP being localized to the activated synapse and not induced at other synapses of 
the same neuron (Bliss and Collingridge, 1993; Rison and Stanton, 1995). 
The requirements for the induction of LTP can be linked to the unique properties of 
NMDA receptors and the organization of the synapse.  The presynaptic release of glutamate will 
activate glutamate receptors within the postsynaptic membrane.  Low-intensity activity results in 
the activation and passage of ions through AMPA receptors, while NMDA receptor activity is 
inhibited by Mg2+o.  Higher-intensity activity results in greater AMPA receptor-mediated current 
and depolarization of the postsynaptic site, relieving Mg2+o block of NMDA receptors.  The 
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requirement for presynaptic glutamate release and postsynaptic depolarization intense enough to 
reduce Mg2+o block of NMDA receptors accounts for the associative and cooperative properties 
of LTP.  The activation of postsynaptic NMDA receptors results in the influx of Ca2+, which 
activates various second messenger systems localized to the region of the activated postsynaptic 
site, accounting for the input-specificity of LTP.  The activation of second messengers by Ca2+ 
influx results in synaptic changes, such as increasing the flow of ions through postsynaptic 
receptors, that contribute to the expression of LTP (Bliss and Collingridge, 1993; Rison and 
Stanton, 1995).   
While high levels of synaptic activity are required for LTP induction, lower levels of 
activity can produce LTD (Malenka and Bear, 2004).  NMDA receptors have been implicated in 
the induction of some forms of LTD, since inhibition of NMDA receptors has been shown to 
prevent LTD induction (Dudek and Bear, 1992; Thiels et al., 1996).  Like LTP, it appears that 
increases in intracellular Ca2+ concentrations, likely through activated NMDA receptors, is 
critical for inducing LTD (Mulkey and Malenka, 1992).  The increase in postsynaptic Ca2+ 
concentration resulting from LTD-inducing stimuli is hypothesized to activate a cascade of 
phosphatases that decreases the flow of ions through postsynaptic receptors (Mulkey et al., 
1993).  Thus, it appears that the magnitude of Ca2+ entering the postsynaptic cell through NMDA 
receptors is a crucial factor in determining the direction of change in synaptic strength (Mulkey 
and Malenka, 1992). 
1.3.2 Pathological consequences of NMDA receptor activity 
NMDA receptor blockade can increase the vulnerability of neurons to cell death, especially early 
in development (Ikonomidou et al., 1999; Ikonomidou et al., 2000; Hardingham and Bading, 
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2003).  Administration of NMDA receptor antagonists to perinatal rats has been reported to 
increase neuronal death (Ikonomidou et al., 1999; Lipton and Nakanishi, 1999; Ikonomidou et 
al., 2000).  The increase in neuronal death was observed for various NMDA receptor antagonists 
(MK-801, PCP, ketamine, memantine, or CPP).  Thus, it is suggested that some level of NMDA 
receptor-mediated activity is required for cell growth and survival (Ikonomidou et al., 1999; 
Ikonomidou et al., 2000; Hardingham and Bading, 2003).  The exact mechanism underlying the 
requirement of NMDA receptor activation for neuronal survival is unknown.  One suggested 
mechanism is that excessive inhibition of NMDA receptors can lower intracellular Ca2+ levels.  
This depletion of intracellular Ca2+ will lower the activity of Ca2+-activated signaling molecules 
whose activity promotes cell survival (Ikonomidou et al., 2000; Hardingham and Bading, 2003). 
Excessive activation of NMDA receptors and the resultant Ca2+ influx can also result in 
neuronal cell death.  Thus, high Ca2+ permeability of NMDA receptors appears responsible for 
their influence on the health and survival of neurons.  Pro-survival or pro-death pathways can be 
activated depending on the source as well as degree of Ca2+ influx into a cell.  The exact 
contribution of different Ca2+ sources to the onset of neuronal cell death is still undetermined 
(Hardingham and Bading, 2003). 
1.3.2.1 Excitotoxic cell death 
Excessive glutamate release, resulting from events such as head trauma, can overwhelm 
glutamate transporters and cause hyperactivation of glutamate receptors.  Intense activation of 
NMDA receptors leads to accumulation of Ca2+ in neurons that surpasses the ability of 
endogenous regulators of Ca2+ sequestration.  High concentrations of free intracellular Ca2+ can 
initiate many downstream signaling cascades that can harm the health of neurons.  The 
consequences of these signaling cascades include alteration of mitochondrial function, 
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overactivation of enzymes that produce reactive oxygen species (ROS), reorganization of the 
cytoskeleton, and activation of genetic cell death signals (Choi, 1988; Lodge et al., 2002; 
Hardingham and Bading, 2003; Arundine and Tymianski, 2004; Albensi, 2007).  Triggering of 
these cell death pathways contributes to the pathology of both acute insults and more chronic 
neurodegenerative disorders. 
1.3.2.2 Neuropsychiatric and neurodegenerative disorders 
While severe insults can rapidly initiate NMDA receptor-mediated cell death, mild but chronic 
alterations in NMDA receptor functioning are hypothesized to contribute to many 
neuropsychiatric (such as schizophrenia) and neurodegenerative (such as Alzheimer’s and 
Parkinson’s disease) disorders.  NMDA receptor malfunctioning has also been implicated in 
other diseases, such as neuropathic pain, epilepsy, and glaucoma (Lodge et al., 2002).  Although 
involved in many disease states, the focus of this dissertation will be limited to NMDA receptor 
involvement in schizophrenia and Alzheimer’s disease.   
Schizophrenia is a severe cognitive disorder that typically begins in early adulthood and 
lasts throughout an individual’s lifetime.  The symptoms of schizophrenia have typically been 
separated into three categories: positive, negative, and cognitive.  The positive symptoms include 
hallucinations, paranoia, and agitation, which are believed to result from increases in normal 
CNS functioning.  The negative symptoms of schizophrenia represent those that reflect a 
decrease in CNS functioning, such as dulled emotional responses and social withdrawal.  
Disorientation and conceptual disorganization reflect the cognitive symptoms (Kilts, 2001; 
Lodge et al., 2002; Lindsley et al., 2006).   
Although alterations in the functioning of several neurotransmitter systems have been 
implicated in schizophrenia, much attention has focused on the involvement of the dopaminergic 
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and glutamatergic systems.  The dopamine hypothesis proposes that excessive dopamine receptor 
activity (especially D2 receptors) underlies the positive symptoms of schizophrenia (Seeman, 
2002; Stone et al., 2007).  This hypothesis is based on the clinical observation that 
pharmacological dopamine receptor antagonists are effective in alleviating the positive 
symptoms of schizophrenia (Seeman, 2002; Stone et al., 2007).  The NMDA receptor 
hypofunction hypothesis arose from the observation that NMDA receptor antagonists, such as 
PCP and ketamine are capable of reproducing a wide array of symptoms characteristic of 
schizophrenia in healthy individuals as well as worsen symptoms in already afflicted patients 
(Lindsley et al., 2006; Stone et al., 2007).  The NMDA receptor hypofunction hypothesis claims 
that decreased NMDA receptor-mediated activity is critically involved in the pathology of 
schizophrenia (Lindsley et al., 2006; Stone et al., 2007). 
The glutamatergic and dopaminergic systems interact and modulate the functioning of 
each other (Jedema and Moghddam, 1996; Kiyatkin and Rebec, 1996; Verma and Moghaddam, 
1996; Moghaddam et al., 1997; Adams and Moghaddam, 1998; Takahata and Moghaddam, 
1998; Carr and Sesack, 2000; Sesack et al., 2003; Stone et al., 2007).  Dopamine modulates the 
functioning of glutamatergic projection neurons in the cortex and the hippocampus, areas 
associated with cognition and learning (Kiyatkin and Rebec, 1996; Stone et al., 2007).  Firing of 
glutamatergic neurons also affects the activity of dopaminergic neurons (Jedema and 
Moghddam, 1996; Verma and Moghaddam, 1996; Moghaddam et al., 1997; Adams and 
Moghaddam, 1998; Takahata and Moghaddam, 1998).  Ketamine administration to rats resulted 
in an increase of dopamine release in the prefrontal cortex (Verma and Moghaddam, 1996; 
Moghaddam et al., 1997), demonstrating a functional link between the dopaminergic hypothesis 
and NMDA receptor hypofunction hypothesis of schizophrenia.  However, it is still unclear 
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whether alterations in the dopaminergic or glutamatergic neurotransmitter systems are the first 
step in the onset of schizophrenic pathology. 
Alzheimer’s disease is a progressive form of dementia that affects the elderly.  
Pathological hallmarks of Alzheimer’s disease are the presence of senile plaques and 
neurofibrillary tangles, and a loss of synaptic connections (Butterfield and Pocernich, 2003).  
Senile plaques are comprised of amyloid β-peptide (Aβ) deposits, which are suggested to be 
associated with the neurodegeneration observed in Alzheimer’s disease (Varadarajan et al., 
2000).  Aβ is produced by enzymatic cleavage of the membrane associated protein amyloid 
precursor protein (APP).  Hyperphosphorylation of the microtubule-associated protein tau forms 
neurofibrillary tangles by disrupting microtubule assembly.  Disruption of the microtubule 
system results in cellular dysfunctions contributing to death (Alonso et al., 1997; Varadarajan et 
al., 2000; Chohan and Iqbal, 2006).   
Conventional treatments for Alzheimer’s disease have been aimed at enhancing 
cholinergic neurotransmission by inhibiting cholinesterase (an enzyme that degrades 
acetylcholine) activity.  In fact, it has been suggested that cholinergic transmission controls APP 
cleavage, Aβ plaque formation, and tau phosphorylation (Schliebs and Arendt, 2006).  However, 
it is still unclear whether a deficit in cholinergic transmission is the initiator or a result of 
Alzheimer’s disease.  Much like the proper functioning of the dopaminergic and glutamatergic 
systems is relevant in the pathophysiology of schizophrenia, it is likely that multiple 
neurotransmitter systems are involved in Alzheimer’s disease.  Evidence linking NMDA 
receptors to learning and memory as well as excitotoxic cell death suggests that the 
glutamatergic system is likely to be highly involved in Alzheimer’s disease (Albensi et al., 
2004).  Further supporting NMDA receptor involvement in the pathology of Alzheimer’s disease 
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is evidence that NMDA receptor activity stimulates Aβ production (Butterfield and Pocernich, 
2003) and NMDA receptor-dependent synaptic transmission is suppressed by Aβ (Butterfield 
and Pocernich, 2003; Kamenetz et al., 2003).  Aβ also causes a loss of excitatory terminals in the 
cortex (Bell and Claudio Cuello, 2006) and NMDA receptor internalization (Snyder et al., 2005).  
The ability of the NMDA receptor antagonist memantine to slow the cognitive decline of 
moderate-to-severe Alzheimer’s disease also links NMDA receptor activity to the disease 
(Parsons et al., 1999; Farlow, 2004; Lipton, 2004a; Winblad et al., 2007). 
1.3.3 Behavioral effects of NMDA receptor inhibition 
Increased NMDA receptor activity is implicated in a variety of disease states; however, 
pharmacological attempts at preventing pathological NMDA receptor overactivation have 
generally been less than promising.  Among other problems, many NMDA receptor antagonists 
are associated with debilitating psychotomimetic side-effects.  While therapeutically this side-
effect profile has hindered the clinical utility of many NMDA receptor antagonists, it has also 
greatly furthered our understanding of diseases characterized by NMDA receptor hypofunction, 
especially schizophrenia. 
1.3.3.1 Human effects 
The effects of the dissociative anaesthetics, PCP and ketamine, in humans have been well 
characterized.  The main action of these drugs is suggested to be use-dependent inhibition of 
NMDA receptor-mediated neurotransmission (Bormann, 1989; Kornhuber et al., 1989; 
Yamamura et al., 1990; Witt et al., 2004).  PCP and ketamine have been crucial tools in the study 
of schizophrenia.  Human psychopharmacological research has shifted towards ketamine rather 
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than PCP due to the lower abuse potential of ketamine and its shorter plasma half-life which 
allows for greater control of plasma levels (Krystal et al., 2003).  The use of ketamine to model 
schizophrenia in humans is based on a variety of observations.  The strongest support comes 
from ketamine’s ability to transiently mimic the symptoms of schizophrenia in healthy adults 
(Newcomer et al., 1999; Krystal et al., 2003) as well as transiently worsen symptoms in 
individuals already afflicted with schizophrenia (Lahti et al., 1995; Malhotra et al., 1997; Krystal 
et al., 2003).   
Although ketamine has been widely accepted as a pharmacological model of 
schizophrenia, some discrepancies exist between the effects of ketamine and the disorder.  
Ketamine administered to schizophrenic patients in remission resulted in psychotic relapse.  The 
symptoms exhibited during the relapse were typical for a given patient; however, these 
symptoms were not ameliorated by pretreatment with the typical antipsychotic haloperidol 
(Krystal et al., 1999a).  Another difference between ketamine’s effects and the symptomatic 
profile of schizophrenia is the ability of ketamine to produce sedative and euphoric effects 
similar to alcohol (Krystal et al., 2003).   
1.3.3.2 Ketamine as an animal model of schizophrenia 
Administration of the NMDA receptor antagonists PCP, ketamine, or MK-801 leads to behaviors 
in rat that have been correlated to the symptoms of schizophrenia in humans (Lipska and 
Weinberger, 2000; Kilts, 2001; Tordjman et al., 2007).  Psychomotor agitation in humans is 
correlated with increased locomotor activity in rats (Hetzler and Wautlet, 1985; Danysz et al., 
1994; Koros et al., 2007).  Also both schizophrenic humans and rats administered dissociative 
anaesthetics exhibit spatial working memory deficits (Verma and Moghaddam, 1996; Jackson et 
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al., 2004), stereotypic behavior, and decreased social behavior (Danysz et al., 1994; Lipska and 
Weinberger, 2000; Kilts, 2001; Koros et al., 2007; Tordjman et al., 2007).   
1.3.4 NMDA receptors as therapeutic targets 
Some NMDA receptor antagonists demonstrate potential in alleviating the symptoms of many 
disorders; however, their usefulness has been hindered by the debilitating side-effects discussed 
previously.  Surprisingly, despite the psychotomimetic side-effects elicited by NMDA receptor 
antagonists in healthy human adults, these side-effects are much less severe in children.   
Despite the intolerability of many NMDA receptor antagonists, the antagonist memantine 
is reported to be generally safe.   Furthermore, memantine has clinical value in its ability to slow 
the progressive cognitive decline associated with moderate-severe Alzheimer’s disease (Witt et 
al., 2004). 
1.3.4.1 Memantine and Alzheimer’s disease 
Although generally well tolerated (Parsons et al., 1999; Rogawski and Wenk, 2003; Witt et al., 
2004; Sonkusare et al., 2005), there have been reports of probable Alzheimer’s patients 
experiencing visual hallucinations and agitation about a week after having memantine (5 
mg/day) added to their combination treatment (Monastero et al., 2007).  However, controlled 
studies of patients with moderate to severe Alzheimer’s disease have shown that the overall 
incidence of adverse reactions to memantine was not different than the incidence of these 
reactions to placebo (Mobius, 2003).      
Memantine administered to rats induced behavioral effects that were similar, yet less 
prominent, than those induced by ketamine.  The behavioral effects included increased horizontal 
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activity, decreased rearings, and decreased social interaction (Danysz et al., 1994; Koros et al., 
2007).  It should also be mentioned that the doses of memantine administered to the rats in these 
studies was much higher than those given to individuals receiving typical treatment regimens.   
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2.0  BINDING AT SUPERFICIAL SITE ON NR1/2A NMDA RECEPTORS 
CONTRIBUTES TO PARTIAL TRAPPING OF MEMANTINE 
2.1 ABSTRACT 
Memantine lacks the behavioral side-effects of conventional NMDA receptor channel blockers, 
such as ketamine and phencyclidine (PCP) and slows the progressive cognitive decline 
associated with Alzheimer’s disease.  Memantine and ketamine inhibit NMDA receptors with 
similar affinity and kinetics at a site that overlaps the binding site for Mg2+o.  A prominent 
mechanistic difference between inhibition by memantine or ketamine is the degree to which they 
are trapped within the channel of closed NMDA receptors.  Here, we have investigated the 
mechanism underlying partial trapping of memantine by recombinant NR1/2A NMDA receptors.  
We measured a time course (τ = 0.78 ± 0.29 s) for the dissociation of memantine from NR1/2A 
receptors; this time course describes the development of partial trapping.  Our data argue against 
open channel escape of memantine during partial trapping development.  We and others have 
measured memantine inhibition of NMDA receptors in the absence of agonist, an effect that has 
not been observed with ketamine.  Based on our observations we conclude that partial trapping 
of memantine results from competitive binding of memantine at a superficial “non-trapping” site 
and the deep “trapping” site.  Memantine binding at the superficial site may, by causing partial 
trapping, contribute to memantine’s unique therapeutic utility and clinical effectiveness. 
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2.2 INTRODUCTION 
Despite differences in tolerability, memantine and ketamine are both activity-dependent NMDA 
receptor channel blockers with comparable affinities and kinetics.  These drugs require agonist 
binding and channel opening for access to their binding site (Chen et al., 1992; Parsons et al., 
1995; Blanpied et al., 1997; Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Mealing et 
al., 1999; Bolshakov et al., 2003).  Channel closure and agonist dissociation can occur while 
either drug is bound, effectively trapping the drug within the receptor’s channel until subsequent 
agonist binding again allows channel activation and blocker dissociation.  The ability of channel 
blockers to enter into this trapped state varies among different NMDA receptor trapping channel 
blockers.  Ketamine has been classified as a “full trapping” channel blocker, because all (or 
nearly all) molecules bound to NMDA receptors following dissociation of agonist remain bound 
until further channel activation (Mealing et al., 1999).  Memantine has been classified as a 
“partial trapping” channel blocker because a fraction of memantine molecules bound to NMDA 
receptors immediately after agonist removal has been shown to unbind before channels are 
subsequently activated by reapplication of agonist (Blanpied et al., 1997; Chen and Lipton, 1997; 
Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Mealing et al., 1999).  Hypotheses 
have been put forth to explain how the non-trapped fraction of partial trapping blockers 
dissociates from NMDA receptors (Blanpied et al., 1997; Mealing et al., 2001; Bolshakov et al., 
2003); however, the mechanism remains unclear. 
In some studies that examined the mechanism responsible for the varied degrees of 
trapping of NMDA receptor channel blockers, partial trapping compounds were hypothesized to 
leave the channel through an open state (Blanpied et al., 1997; Bolshakov et al., 2003).  Proposed 
“open-channel escape” mechanisms include the ideas that memantine binding increases agonist 
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affinity and gating transitions into the open state (Blanpied et al., 1997), and that partial trapping 
compounds bind at a second site that prevents channel closure (Bolshakov et al., 2003).  Mealing 
et al. (2001) proposed the presence of a second “trapping gate” (distinct from the gate that 
regulates ion permeation) that closes slowly compared to the unbinding rate of partial trapping 
compounds.  However, this same group also reported that differences in the degree of trapping 
exist among use-dependent NMDA receptor antagonists that have similar binding and unbinding 
kinetics, arguing against a compounds unbinding kinetics being the sole contributor to partial 
trapping (Mealing et al., 1999).   
Although capable of explaining how partial trapping can occur, these hypotheses are not 
entirely consistent with experimental observations.  A problem associated with open-channel 
escape models of partial trapping is that one would expect to observe current flowing through 
receptors that have released blocker upon the removal of agonist and blocker before channels 
have had the time to close.  This “tail current”, which is observed for sequential (foot-in-the-
door) blockers that do not allow channel closure while bound (Benveniste and Mayer, 1995), is 
rarely observed with memantine (Blanpied et al., 1997).  These observations suggest that 
minimal memantine dissociation occurs through open channels.   
Memantine passage through a lipophilic pathway is an alternative hypothesis to open-
channel escape; however, previous studies have shown no correlation between the lipophilicity 
of a compound and its degree of trapping (Mealing et al., 1999; Mealing et al., 2001).  The 
observation that trapping does not continually decrease during extended wash periods (Blanpied 
et al., 1997) also argues against a lipophilic pathway for blocker escape.   
A characteristic of NMDA receptor inhibition by memantine that may contribute to 
partial trapping and deserves further evaluation is the possibility that memantine can inhibit 
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NMDA receptors by binding at two sites.  The principal binding site for memantine, as well as 
ketamine, is located deep within the voltage field of NMDA receptor channels and is only 
accessible to channel blockers upon receptor activation.  Previous studies suggest the presence of 
a second binding site for memantine; however, the location and characteristics of the second site 
are less clear than for the principal binding site (Blanpied et al., 1997; Sobolevsky and Koshelev, 
1998; Sobolevsky et al., 1998; Chen and Lipton, 2005).  Evidence places this second site 
shallower within the voltage field of NMDA receptors than the trapping site (Blanpied et al., 
1997; Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Chen and Lipton, 2005).  
Blanpied et al. (1997) showed that memantine can bind to and inhibit NMDA receptors at a 
second “superficial” site that is accessible in the absence of agonists.  It is unknown whether or 
not ketamine can bind to the superficial site.  A careful characterization of the superficial site 
may help further our understanding NMDA receptor functioning.   
2.3 MATERIALS AND METHODS 
2.3.1 Cell culture and transfection 
Experiments were performed on the human embryonic kidney (HEK) 293T cell line.  Cells were 
enzymatically dissociated, plated onto glass coverslips coated with poly-D-lysine and collagen 
(Sigma, St. Louis, MO), and incubated at 37º C for 24 hours prior to transfection.  Transfection 
of the NR1-1a (GenBank accession number (ACCN) X63255, in pcDM8) and NR2A (ACCN 
M91561, in pcDM8) NMDA receptor subunit cDNAs, along with eGFP cDNA for identification 
of successfully transfected cells, was performed with Lipofectamine (Invitrogen Corporation, 
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Carlsbad, CA) at a ratio of 1 NR1 : 3 NR2A : 6 eGFP.  200 μM DL-2-amino-5-
phosphonopentanoic acid (DL-APV, Sigma, St. Louis, MO) was added to culture medium at the 
end of transfection to limit excitotoxic activation of expressed NMDA receptors.   
2.3.2 Solutions 
Solutions were prepared from concentrated stock solutions.  The external bath solution (Normal 
Ringers Solution) contained (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, and 10 HEPES.  4-fold lower 
extracellular cation solution (low [ion]o Ringers) consisted of (in mM): 35 NaCl, 0.7 KCl, 0.25 
CaCl2, 10 HEPES.  External solutions were adjusted to a pH of 7.20 ± 0.05 with 6.0 N NaOH, 
and osmolality adjusted to 290 ± 10 mmol/kg with sucrose.  Internal solution contained (in mM): 
125 CsCl, 10 BAPTA, and 10 HEPES.  The pH of the internal solution was adjusted to 7.20 ± 
0.05 with CsOH and osmolality was 275 ± 10 mmol/kg.  A frozen aliquot of internal solution 
was thawed for each day of experiments.  Correction for the junction potential (measured as -6 
mV) was applied to all data. 
2.3.3 Electrophysiology 
Whole-cell patch-clamp recordings were performed on transiently transfected HEK293T cells 
expressing NR1/2A receptors.  Recording electrodes were pulled from standard–walled 
borosilicate glass capillary tubes with filaments (Warner Instruments, Hamden, CT).  Electrode 
tips were heat polished and had a resistance between 2 to 6 MΩ.  Series resistance was 
compensated 80 – 95 % in all experiments.  Whole-cell current responses were recorded with an 
Axopatch-1D amplifier (Molecular Devices, Sunnyville, CA), printed on a thermal arraycorder 
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(Graphtech Corp., Irvine, CA) for monitoring of data quality during experiments, and stored on 
VHS tape for additional analysis.   
A seven-barrel, gravity-fed fast perfusion system (Blanpied et al., 1997) was used for 
solution application to patch-clamped cells.  Currents were activated by application of 10 μM 
NMDA and 10 μM glycine.  Recordings were made at -66 mV unless otherwise stated.  For 
experiments testing the effect of a depolarizing voltage step on the fractional recovery of 
memantine, a voltage step to +54 mV for 5 s was applied using pClamp 9.2 (Molecular Devices, 
Sunnyville, CA).   
The time constant for solution exchange was determined by measuring the decay time 
constant of NMDA receptor-mediated responses when solutions were switched from Normal 
Ringers Solution containing 10 μM NMDA and 10 μM glycine to a solution where 140 mM 
NMDG replaced NaCl.  The exchange time constant determined through this method was 
measured as ~16 ms.  Therefore, the shortest solution application we used was 0.1 s, which was 
greater than 5x our measured solution exchange time constant, allowing us to be sure we have 
achieved at least ~98 % of solution exchange.  We were also concerned with the time needed for 
high concentrations of memantine or ketamine to diffuse away from the cell we were recording 
from.  We measured the decay time constant of current responses upon removal of 10 mM 
NMDA and 10 μM glycine, to determine the time necessary to allow complete diffusion of this 
high NMDA concentration (relative to its EC50) away from the cell.  These measurements 
suggested complete diffusion of this high NMDA concentration occurred within 0.4 s.  
Therefore, 0.4 s is the shortest solution application used when applying relatively high 
concentrations (compared to their IC50 values) of memantine or ketamine to our cells. 
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2.3.4 Analysis 
Data were played back from VHS tapes and low-pass filtered at 2.5 kHz through a Bessel filter 
and digitized using a Digidata 1200 or 1440A (Molecular Devices, Sunnyville, CA) at a 
sampling rate of 5 kHz or 400 Hz and saved using pClamp 9.2 software (Molecular Devices, 
Sunnyville, CA).  Data were again filtered at 100 Hz and decimated by a factor of 10 using 
Clampfit 9.2 (Molecular Devices, Sunnyville, CA) for further analysis. 
Current measurements of interest are indicated in Figure 2 and defined below.  Peak 
current responses to the initial agonist application (Ip) were measured by subtracting baseline 
current from peak current.  Baseline currents were calculated by averaging current within a 500 
ms window.  Peak currents were calculated by averaging current within a 50 ms window 
beginning at the time peak current was observed.  The difference between the time of barrel 
movement and the center of the time window used to measure peak current was termed tP and 
will be used below.   Steady-state current responses (ISS, steady-state current response to initial 
agonist application; IBSS, steady-state current response in the presence of agonist and blocker; 
and ISS2, steady-state current response in the presence of agonist after recovery from block) were 
measured by subtraction of baseline current from the average steady-state current within a 500 
ms window.  Data were rejected if the ISS2 did not recover to 60% of the previous ISS.  IB is the 
initial current jump activated by reapplication of agonist, and exceeds IBSS as a result of partial 
trapping.  The time after barrel movement when IB was measured equaled tP (50 – 250 ms after 
barrel movement).  To determine IB, a single or double exponential was fit to a 1 s window 
during the current response activated by the second agonist application, beginning at a time after 
barrel movement equal to tP.  Baseline current was then subtracted from current value of the 
exponential fit measured at tP after barrel movement to yield IP. 
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Figure 2.  Double-pulse protocol.  Sample trace shows the double-pulse protocol used for 
measuring the fractional recovery of NR1/2A NMDA receptors from inhibition by memantine or 
ketamine (50 μM memantine was used here).  The lines above the current trace in this and 
subsequent figures show time of agonist and blocker applications.   Current measurements of 
interest are indicated in the figure and defined in methods. 
 
 
The residual current during inhibition by each blocker was calculated with the equation: 
Residual Current = IBSS/ISS    (1) 
where IBSS and ISS represent the measurements shown in Figure 2, although the protocol shown 
in Figure 3A, B was used to measure Residual Current. 
Concentration-inhibition curves for the deep site were fit using the equation:  
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IBSS/ISS = 1 / (1 + [B]nH / IC50nH)   (2) 
where [B] is the blocker concentration, and nH is the Hill coefficient.   
The fractional current recovery as a result of blocker unbinding between the blocker plus 
agonist and the agonist application in the double-pulse protocol was calculated by the equation: 
Fractional Recovery = [(IB-IBSS)/ISS2]/(IP/ISS)   (3) 
IP/ISS was included in the equation to account for NMDA receptor recovery from desensitization 
between agonist applications. 
Time constants for the development of partial trapping and dissociation from the 
superficial site were determined by a single exponential fit of fractional recovery as a function of 
time (see Figure 4C) with the equation: 
Fractional Recovery = y0 + Ae-t/τ   (4) 
where y0 is the fractional recovery at time = 0, A is the amplitude of the exponential, t is the 
wash duration, and τ is the time constant. 
The superficial site current recovery resulting from blocker unbinding during a wash 
between blocker application and agonist application (Figure 7) was calculated with the equation: 
Superficial Site Recovery = (IB/ISS2)/(IP/ISS)   (5) 
where IB, ISS2, IP, and ISS represent the measurements shown in Figure 2, although the protocol 
used is shown in Figure 7A, B. 
Concentration-inhibition curves for the superficial site were fit using the equation: 
IBSS/ISS = C1 + (1 - C1) / [(1 + [B]nH  / IC50nH)]  (6) 
where C1 represents the minimal fraction of residual current when blocker is bound at the 
superficial site.    
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Where appropriate, two-tailed Student’s t-test (* p < 0.05 for between group 
comparisons) or one-way ANOVA with Bonferroni post-hoc comparisons (# p < 0.05 for within 
group comparisons) were used. 
2.4 RESULTS 
2.4.1 Time course of blocker dissociation from NR1/2A receptors in the absence of agonist 
We performed whole-cell voltage-clamp recordings on HEK293T cells expressing recombinant 
NR1/2A receptors to examine the mechanism of partial trapping.  Concentration-inhibition 
curves for memantine and ketamine were measured (Figure 3A-C), and the resultant IC50 values 
were 1.25 ± 0.04 μM and 0.35 ± 0.01 μM, respectively.  These values are similar to those 
reported previously (Parsons et al., 1995; Blanpied et al., 1997; Sobolevsky and Koshelev, 1998; 
Sobolevsky et al., 1998; Mealing et al., 1999; Kashiwagi et al., 2002).  We chose to study partial 
trapping of memantine at 50 μM, a concentration consistent with that used in previous work 
(Blanpied et al., 1997), and wanted to chose a ketamine concentration so that we had similar 
residual current in ketamine as well as in memantine.  Based on our IC50 measurements we 
calculated that 15 μM ketamine yields residual current comparable to that observed with 50 μM 
memantine (Figure 3C).   
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Figure 3.  NMDA receptor inhibition by memantine and ketamine.  A and B, Representative 
current traces recorded at -66 mV from transfected HEK293T cells demonstrating the 
concentration dependence of NR1/2A receptor inhibition by memantine (A) and ketamine (B).   
C, Memantine (filled circles) and ketamine (open circles) concentration-inhibition curves.  Solid 
and dashed lines are fits (eqn (2)) to the memantine (n = 4) and ketamine (n = 4) data, 
respectively.   
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We measured the time course for the dissociation of non-trapped memantine from 
NR1/2A receptors in the absence of agonist that results in partial trapping.  A double-pulse 
protocol was used (Figure 4A, B).  The interval between the removal of agonist and memantine 
and the subsequent application of agonist to our cells was varied, which allowed us to measure 
the development of fractional recovery from the trapped state.  The briefest wash duration used 
here (0.1 s) was chosen based on our measurements of solution exchange time (Methods), so we 
could be sure that memantine was no longer present in the solution surrounding the cell when 
agonist was reapplied.  Our data show that the fractional recovery of memantine inhibition 
developed with a time constant of 0.78 ± 0.29 s (Figure 4A, C).  The fractional recovery of 
memantine inhibition was significantly different from the residual current measured, when 
memantine was applied in the presence of agonist, across the wash durations tested (p < 0.05, 
ANOVA).  ANOVA followed by Bonferroni post-hoc tests show that the fractional recovery of 
memantine inhibition at all wash durations tested was significantly greater than the residual 
current measured in the presence of memantine and agonist (p’s < 0.05).  A time constant of 0.58 
± 0.30 s was measured when this experiment was performed with ketamine (Figure 4B, C).  
There was also a significant effect of wash duration on fractional recovery of ketamine inhibition 
(p < 0.05, ANOVA).  Although these results suggest that ketamine exhibits slight partial 
trapping, fractional recovery from inhibition was significantly lower with ketamine than with 
memantine at all wash durations tested (p’s < 0.05, Figure 4C). 
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Figure 4.  Time course of partial trapping development.  A and B, NR1/2A receptor current 
traces during the double-pulse protocol that were used to measure the time course of recovery in 
the absence of agonist from inhibition by 50 μM memantine (A) or 15 μM ketamine (B).  The 
break in the traces represents the wash duration which was varied (a wash duration of 15 s is 
shown in the sample traces).  C, Plot of the time dependence of the fractional recovery from 
inhibition (see eqn (3)) by memantine (filled circles) or ketamine (open circles).  Solid and 
dashed lines are single exponential fits (eqn (4)) to memantine and ketamine data, respectively.  
Residual responses (see eqn (1)) in the presence of memantine and ketamine are plotted as 
IBSS/ISS.  The results are displayed as means ± SEM of 6 (memantine) or 4 (ketamine) cells.  # 
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significantly (p < .05) different from respective IBSS/ISS (Bonferroni test).  * significantly (p < 
.05) different between drugs (Student’s t-test). 
 
 
2.4.2 Partial trapping is not the result of open-channel escape 
The unbinding rate of memantine from activated NMDA receptors increases as membrane 
voltage depolarizes (Parsons et al., 1993; Parsons et al., 1995; Parsons et al., 1996; Blanpied et 
al., 1997).  We tested the contribution of the unbinding rate on the fractional recovery of 
memantine inhibition by applying a 5 s voltage jump to +54 mV (Figure 5A) during and after the 
time our previous data (Figure 4C) suggested partial trapping develops.  If partial trapping of 
memantine results from escape through open channels, then the depolarizing voltage step should 
increase fractional recovery when applied shortly after removal of agonist and blocker from our 
cells.  Figure 5B demonstrates no significant difference (ANOVA) of depolarizing voltage steps 
on the fractional recovery of memantine inhibition compared to controls, for which no voltage 
step was applied. 
To further examine any contribution of unbinding rate to partial trapping, we followed an 
approach similar to that of Mealing et al. (2001), and modified the double-pulse protocol by 
continuing the application of memantine after the end of the agonist application (Figure 5C).  
Thus, a constant concentration of memantine was present throughout the time when non-trapped 
memantine dissociates (Figure 4C).  We used this protocol to test the hypothesis that partial 
trapping is due to rapid memantine unbinding from the deep site before receptors close after 
removal of agonist and memantine.  If this hypothesis is correct, then the continued presence of 
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memantine should maintain occupancy of the deep site, resulting in less fractional recovery.  We 
found no significant change in the fractional recovery of memantine inhibition due to this 
extended application, compared to the double-pulse protocol in which memantine and agonist 
were removed simultaneously (Figure 5D).  We feel that this result combined with the results of 
voltage jump experiments (Figure 5B) provide strong evidence that the relatively fast unbinding 
rate of memantine cannot fully explain its partial trapping by NR1/2A receptors. 
 
 
 
A B 
C D 
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Figure 5.  Non-trapped memantine does not escape from open channels.  A, Voltage (upper) and 
current (lower) traces demonstrating the protocol used.  Experiments were performed at -66 mV 
with 5 s depolarizing voltage steps to +54 mV beginning 0.1 – 10 s after removal of agonist and 
blocker.  The break in the traces represents the time between agonist removal and agonist 
reapplication, which was varied (sample trace shows a 10 s wait before voltage step application).  
B, Membrane depolarizations applied during and after the development of partial trapping of 50 
μM memantine had no significant effect (ANOVA) on fractional recovery (n = 5).  Control data 
represent measurements made without a voltage step.  C, Current trace demonstrating the 
modified trapping protocol.  The modified trapping protocol was similar to the double-pulse 
protocol (Figure 2), except that blocker application was extended past the time when agonist 
application ended.  Thus, blocker was present throughout the time when partial trapping 
developed (Figure 4C).  D, Effects of the modified trapping protocol on fractional recovery of 
memantine inhibition.  The continued presence of 50 μM memantine during the development of 
partial trapping (grey bar) had no significant effect (Student’s t-test) on memantine trapping (n = 
4).  The normal “Trapping Protocol” data point (black bar) is replotted in Figure 8E (-66 mV 
memantine data). 
 
 
2.4.3 NR1/2A receptor inhibition in the absence of agonist 
Our finding that open-channel escape cannot fully account for the partial trapping of memantine 
led us to test a closed-channel mechanism.  We explored the possibility that non-trapped 
memantine dissociates from a second inhibitory site from which unbinding can occur when the 
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channel is closed.  When the channel is open there is competition between this site and the deep 
site for memantine binding (Figure 6).  A previous study from this lab (Blanpied et al., 1997) 
demonstrated that memantine inhibits NMDA receptor currents at a superficial site accessible in 
the absence of agonist.  We decided to test the hypothesis that memantine binding to and 
unbinding from this superficial site contributes to its partial trapping.   
 
 
 
 
Figure 6.  Competitive binding hypothesis of partial trapping of memantine.  We hypothesized 
that partial trapping of memantine by NMDA receptors is the result of competitive binding at 
two inhibitory binding sites that cannot be occupied simultaneously.  Blocker (represented by an 
open circle with +) can only be trapped when occupying the deep trapping site (bottom left).  
Blocker binding and unbinding at the deep site requires channel activation and is strongly 
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voltage-dependent.  Memantine or ketamine can bind at this deep site (left side).  Binding and 
unbinding of blocker at the superficial non-trapping site (right side) may occur whether or not 
channels are activated.  Memantine but not ketamine (right side) can bind at the superficial site, 
which is located external to a trapping gate (broken line).  Memantine unbinding from the 
superficial site after channel closure is hypothesized to result in partial trapping. 
 
 
We measured a time course for memantine unbinding from the superficial site of NR1/2A 
receptors in the absence of agonist.  If our hypothesis is correct, than we predict that this time 
course should be similar to the time course we measured for partial trapping development 
(Figure 4C).  To measure the unbinding rate of memantine from the superficial site, we applied 
500 μM memantine to our cells for 1 min in the absence of agonist, so that the deep site was 
inaccessible to blocker, varied the duration of a subsequent wash (0.4 – 15 s), and then reapplied 
agonist (Figure 7A, C).  The high concentration of memantine was chosen because previous 
measurements (Blanpied et al., 1997) suggested that this site has a very low affinity for 
memantine.  The peak current after agonist application revealed the extent of memantine 
inhibition resulting from occupancy at the superficial site.  These experiments resulted in a time 
constant of τ = 1.94 ± 0.19 s for memantine unbinding from the superficial site (Figure 7C).  
There was a significant effect of wash duration on the recovery from occupancy at the superficial 
site by memantine (p < 0.05, ANOVA).  Post-hoc tests showed a wash duration of either 3, 10, 
or 15 s resulted in significantly greater recovery from superficial site inhibition compared to the 
shortest wash duration, 0.4 s (p’s < 0.05). 
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If partial trapping results from unbinding of memantine from the superficial non-trapping 
site, then the more fully trapped NMDA receptor channel blocker ketamine should exhibit much 
lower or no affinity at the superficial site.  When we carried out the same experiment with 
ketamine (Figure 7B) we observed no significant (ANOVA) superficial site inhibition (Figure 
7C), which suggests that ketamine inhibits NR1/2A receptors by binding only at the deep site.  
We measured significantly less recovery from memantine inhibition at the superficial site 
compared to the amount of recovery from ketamine at that site when wash durations of either 
0.4, 1, or 3 s were applied (p’s < 0.05).    
To test how effectively memantine inhibits at the superficial site, we used the same 
protocol as shown in Figure 7A, and varied the concentration of memantine we applied in the 
absence of agonist.  We measured, at the superficial site, an IC50 for memantine of 79.1 ± 20.2 
μM at NR1/NR2A receptors at -66 mV, when a 0.4 s wash was applied between the application 
of memantine and the application of agonist (Figure 7D).  
To be sure that our concentration-inhibition measurements represent steady-state 
inhibition at the superficial site, we varied the application for the lowest dose of memantine 
tested, 50 μM, in Figure 7D.  The same protocol as shown in Figure 7A was used in these 
experiments, but the application of memantine in the absence of agonist was varied from 30 to 
240 s.  We found no significant effect of application duration (ANOVA) on the amount of 
inhibition at the superficial site by 50 μM memantine (Figure 7E), which suggests that the 
measurements presented in Figure 7D represent steady-state inhibition. 
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Figure 7.  NMDA receptor inhibition by memantine but not ketamine at the superficial site.  A 
and B,  NR1/2A receptor current traces demonstrating the protocol used to measure memantine 
and ketamine inhibition in the absence of agonist.  The wash duration following the application 
of 500 μM memantine (A) or 500 μM ketamine (B) and before the subsequent application of 10 
μM NMDA was varied to measure the time constant of blocker unbinding from the superficial 
site.  The traces presented are examples of a 0.4 s wash application.  C, Measurements of the 
time course of recovery from inhibition at the superficial site by either 500 μM memantine (filled 
circles) or 500 μM ketamine (open circles) in the absence of agonist.  Solid line is a single 
exponential fit (eqn (4)) to the data for 500 μM memantine (n = 4).  Recovery from block by 
memantine at the superficial site was significantly affected by wash duration (p < 0.05, ANOVA) 
.  Dashed line is a linear fit to the data for 500 μM ketamine (n = 4).  There were no significant 
  42
differences (ANOVA) in recovery from block by ketamine between wash durations.  D, 
Memantine concentration-inhibition curve for the superficial site.  Measurements were gathered 
with the protocol demonstrated in A (wash duration of 0.4 s between memantine application and 
subsequent agonist application).  Solid line represents the fit (eqn (6)) to the memantine data.  E, 
The effect of the duration of memantine application in the absence of agonist on steady-state 
inhibition of NR1/NR2A receptors by 50 μM memantine (n = 3).  The protocol was similar to 
the that shown in A, except the duration of memantine application was varied and the wash 
between memantine application and subsequent agonist application was held constant at 0.4 s.  
There were no significant differences (ANOVA) between the data points.  # significantly (p < 
0.05) different from respective 0.4 s wash (Bonferroni test).  * significantly (p < 0.05) different 
between drugs (Student’s t-test). 
 
 
2.4.4 Voltage dependence of trapping 
Blanpied et al. (1997) presented evidence that the superficial memantine binding site is located 
shallower within the voltage field of NMDA receptors than the deep site.  This observation 
implies that memantine binding at the superficial site is less voltage dependent than the deep site.  
Thus, membrane voltages depolarized from rest should lead to greater superficial site binding, 
relative to binding at the deep site, and to less trapping.  Bolshakov et al. (2003) demonstrated 
that the degree of trapping of a variety of NMDA receptor channel blockers is voltage dependent.  
We measured the fractional recovery from block by trapping of either memantine or ketamine in 
the channel of NR1/2A receptors voltage clamped at either -26, -66, and -106 mV (Figure 8A - 
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D).  Memantine and ketamine concentrations were adjusted in these experiments to achieve a 
similar amount of inhibition at each voltage (Table 1), to prevent different amounts of blocker 
binding affecting our results.  Our measurements demonstrate that the fractional recovery of 
inhibition by memantine is significantly dependent upon voltage (p < 0.05; ANOVA).  Post-hoc 
tests showed the fractional recovery from inhibition by memantine at -106 mV tended to be less 
than that at -66 mV.  Significantly more fractional recovery was observed at -26 mV than at -66 
mV (p < 0.05, Figure 8 E).  Consistent with our hypothesis, membrane voltage had less of an 
effect on the fractional recovery of ketamine inhibition (Figure 8C, D, E).  Although there was a 
significant effect of membrane voltage on the fractional recovery of ketamine inhibition (p < 
0.05; ANOVA), post-hoc testing showed that the amount of fractional recovery at neither -26 
mV nor at -106 mV differed significantly from that measured at -66 mV.  The fractional 
recovery of memantine inhibition at -66 mV and at -26 mV each were found to be significantly 
different from the fractional recovery of ketamine inhibition at the corresponding membrane 
voltages (p’s < 0.05). 
It is important to note that depolarization of the membrane voltage significantly affected 
the unbinding time constant of both memantine and ketamine from NR1/2A receptors (p’s < 
0.05, ANOVA, Table 1).  Post-hoc tests showed that the unbinding time constant of memantine 
at -26 mV was significantly faster than that at -66 mV; and the unbinding time constant of 
ketamine at -106 mV was significantly slower than that at -66 mV (p < 0.05).  Significant 
differences in the unbinding time constants between memantine and ketamine were found at all 
voltages tested (p’s < 0.05).  Although unbinding kinetics likely contributes to partial trapping, 
Figure 5B and D provide strong evidence that unbinding rate cannot be solely responsible. 
 
Residual current values and unbinding time constants are presented as means ± SEM.  # significantly (p < 0.05) different from 
respective value at -66 mV (Bonferroni test).  * significantly (p < 0.05) different between drugs (Student’s t-test). 
Table 1.  Residual current and unbinding time constant of memantine and ketamine at concentrations used to measure voltage 
dependence of trapping 
Voltage 
(mV) 
[Mem] 
(μM) 
IMem/IControl Unbinding Time Constant
(s) 
[Ket]
(μM)
IKet/IControl Unbinding Time Constant
(s) 
-26 180 0.020 ± 0.006 4.24 ± .42   # * 55 0.035 ± 0.002 11.2 ± 1.4   * 
-66 50 0.020 ± 0.002 9.73 ± .49   * 15 0.044 ± 0.007 15.1 ± 1.4   * 
-106 15 0.017 ± 0.007 8.76 ± 1.23   * 5 0.056 ± 0.003 25.8 ± 1.5   # * 
  45
 
 
 
 
 
 A B 
C D 
E 
 
Figure 8.  Effect of membrane voltage on fractional recovery of memantine and ketamine 
inhibition.  A and B,  Current traces recorded with the double-pulse protocol at -26 mV (A) and -
106 mV (B) demonstrating the voltage dependence of memantine trapping.  C and D, Current 
traces recorded at -26 mV (C) and -106 mV (D) demonstrating the voltage dependence of 
  46
ketamine trapping.  E, Comparison of the effect of membrane voltage on fractional recovery 
from either memantine or ketamine inhibition.  Inhibitor concentrations used at each voltage are 
listed in Table 1.  Overall, the data show that fractional recovery of memantine inhibition is more 
strongly dependent on membrane voltage than recovery from ketamine inhibition.  # memantine 
significantly (p < 0.05) different from respective value at -66 mV (Bonferroni test).  * 
significantly (p < 0.05) different between drugs (Student’s t-test). 
 
 
2.4.5 Effects of [ion]o on memantine trapping 
We tested the possibility that the superficial memantine binding site overlaps with the external 
cation binding site (Antonov et al., 1998; Antonov and Johnson, 1999; Zhu and Auerbach, 
2001a, b).  If the external cation binding site and the superficial memantine binding site overlap, 
then we may be able to alter memantine binding at the superficial site, relative to the deep site, 
by changing external ion concentration.  We tested the effect of extracellular ion concentration 
([ion]o) on the degree of memantine trapping by decreasing the [ion]o of our solutions 4-fold 
(low [ion]o Ringers) . 
We first measured the effect of a 4-fold reduction of [ion]o on the IC50 of memantine.  
The overall IC50 of memantine in the low [ion]o solution (0.86 ± 0.03 μM) was slightly lower 
than that in Normal Ringers solution (1.25 ± .04 μM; Figure 9A), consistent with the previous 
observation that lowering external cation concentration slightly lowers the IC50 of Mg2+o (Qian et 
al., 2002).  When we tested the effect of [ion]o on superficial site recovery of memantine 
inhibition we found a significant effect of wash duration, similar to what we found when using 
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Normal Ringers solution (p < 0.05, ANOVA, Figure 9B).  Post-hoc tests revealed that the 
recovery from inhibition at the superficial site in low [ion]o was significantly greater after a wash 
duration of either 3, 10, or 15 s compared to recovery from inhibition after the shortest wash 
duration tested, 0.4 s.  Significant differences in recovery from inhibition by memantine at the 
superficial site between Normal Ringers solution and [low]o solution were found at wash 
durations of either 0.4, 1, and 3 s (p’s < 0.05). 
 
 
 
A B 
C 
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Figure 9.  Effect of [ion]o on memantine trapping.  A, Memantine concentration-inhibition 
curves recorded at -66 mV.  Normal Ringers solution data (filled black circles, solid line) are 
replotted from Figure 3C.  Decreasing [ion]o 4-fold (n = 4) slightly decreased the IC50 for 
memantine at NR1/2A receptors(open grey circles, dashed line) relative to the IC50 measured in 
control solution (filled black circles).  B, Low [ion]o affects the unbinding of 500 μM memantine 
from the superficial site of NR1/NR2A receptors.  Normal Ringers solution data (filled black 
circles, solid line) are replotted from Figure 7C (memantine data).  Low [ion]o (n = 3) increased 
memantine binding to the superficial site (open grey circles, dashed line) and decreased 
unbinding rate (τ = 3.45 ± 0.52 s) compared to control solutions (τ = .1.94 ± 0.19 s).  C, Low 
[ion]o significantly increased the fractional recovery of memantine inhibition.  The Normal 
Ringers Solution (black bar) data are replotted from Figure 8E (-66 mV memantine data).  Low 
[ion]o concentration (open grey bar) (n = 4) significantly decreased (p < 0.05, Student’s t-test) 
trapping of memantine (50 μM).  # significantly (p < 0.05) different from respective 0.4 s wash 
(Bonferroni test).  * significantly (p < 0.05) different between extracellular solutions (Student’s 
t-test). 
 
 
  Because decreasing [ion]o increased memantine binding at the superficial site, we 
should also observe less trapping of memantine by NR1/2A receptors if our two-site competition 
hypothesis is correct.  Consistent with our hypothesis we observed significantly greater fractional 
recovery of memantine inhibition when we performed the double-pulse protocol in low [ion]o 
solution (p < 0.05, Figure 9C).  
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2.5 DISCUSSION 
A lack of consensus on the mechanism of partial trapping (Blanpied et al., 1997; Chen and 
Lipton, 1997; Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Mealing et al., 1999; 
Mealing et al., 2001; Bolshakov et al., 2003), as well as inconsistencies between proposed 
hypotheses and experimental data, led us to explore further the mechanism by which memantine 
is partially trapped by NR1/2A NMDA receptors.  Memantine binding to two separate sites on 
NMDA receptors was demonstrated previously (Blanpied et al., 1997; Sobolevsky and Koshelev, 
1998; Sobolevsky et al., 1998; Chen and Lipton, 2005), a property that was found not to apply to 
the full trapping NMDA receptor channel blocker ketamine.  We tested the hypothesis that the 
partial trapping of memantine is the result of competitive binding at two sites on NR1/2A 
receptors, that cannot be occupied simultaneously; a deep trapping site and a superficial non-
trapping site that is accessible regardless of whether the channel is open or closed (Figure 6). 
2.5.1 Partial-trapping development 
We determined that non-trapped memantine dissociates from NR1/2A receptors over a time 
course of τ = 0.78 ± 0.29 s (Figure 4C).  The fractional recovery of memantine inhibition was 
measured to be ~17 %, which is consistent with measurements by others (Blanpied et al., 1997).  
We also found evidence that, during the time partial trapping develops, non-trapped memantine 
does not escape from an open channel (Figure 5B, D).    The fractional recovery of ketamine 
inhibition we measured was significantly less than that of memantine inhibition at all of the wash 
durations tested (Figure 4C).  The small amount of fractional recovery we measured with the 
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full-trapping blocker, ketamine, may have arisen from an effect of ketamine on NMDA receptor 
desensitization, which we attempted to but could not fully control for.   
2.5.2 Memantine inhibition of NR1/2A receptors in the absence of agonist 
If the competitive binding hypothesis is correct, unbinding from the superficial site should follow 
a time course similar to that measured for the development of partial trapping.  The previous 
estimate of the unbinding time constant of memantine from the superficial site of NMDA 
receptors was very similar to the time constant measured for unbinding from the deep site 
(Blanpied et al., 1997), and much slower than what we measured for partial trapping 
development (Figure 4C).  The protocol previously used to measure unbinding from the 
superficial site may have allowed memantine to reach the deep site.  Repeated brief agonist 
applications were delivered in short intervals 1 s after the washout of memantine from the cell.  It 
is possible that memantine bound at the superficial site during the first agonist application after 
memantine washout could have been pulled through the membrane voltage field towards the 
deep site and trapped upon agonist removal.  Subsequent agonist applications in the absence of 
memantine then would have measured memantine escape from the deep site, leading to the 
similar unbinding time constants reported for both sites.  Our measurements of inhibition at the 
superficial site were based on the first application of agonist after blocker exposure (Figure 7A, 
B), which should have prevented deep site binding.  The unbinding time constant of memantine 
we measured at -66 mV for unbinding from the superficial site (τ = 1.94 ± 0.19 s, Figure 7C) is 
much faster than the time constant for unbinding from the deep site (τ = 9.73 ± 0.49 s, Table 1), 
and closer to that measured for the development of partial trapping (τ = 0.78 ± 0.29 s).  Although 
the time constants we measured for the development of partial trapping and memantine 
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unbinding from the superficial site are not the same, there are inaccuracies inherent in the 
indirect way our measurements were made.  Thus, it is plausible that the time course of partial 
trapping development does reflect memantine unbinding from the superficial site.  Ketamine did 
not inhibit NR1/2A-mediated responses at the superficial site (Figure 7C), which suggests that 
ketamine inhibition of NMDA receptors can occur only at the deep trapping site.   
The memantine IC50 we measured for the superficial site (79.1 ± 20.2 μM, Figure 7D) is 
lower than the IC50 reported previously (Blanpied et al., 1997).  Possible explanations for the 
differences between our measurements and those of Blanpied et al. (1997) include receptor 
subunit composition and curve fitting of the data.  Blanpied et al. measured a memantine 
superficial site IC50 at NMDA receptors expressed in cultured cortical neuron that express NR1, 
NR2A, and NR2B subunits and reported an IC50 value of 179 μM, at -67 mV.  The data 
presented here were gathered for NR1/2A receptors transiently transfected into HEK293T cells.  
It is unclear how the presence of NR2B subunits, as well cell type, might affect memantine IC50 
for the superficial site.   
Furthermore, our concentration-inhibition data was best fit with maximal inhibition by 
memantine at the superficial site being ~50 % (Figure 7D).  Blanpied et al. (1997) fit their data 
with an equation that assumed 100 % inhibition at high memantine concentration.  Since we 
waited 0.4 s after blocker washout before agonist was applied, allowing some memantine 
unbinding, maximum inhibition could not be 100 %.  Therefore, our data were fit with a curve 
that allowed maximum inhibition at the superficial site to be adjustable.  
 We used a kinetic model of NMDA receptors to determine whether competitive binding 
of memantine at a superficial site and the deep trapping site would result in partial trapping (data 
not shown).  Model simulations reproduced partial trapping, but with a trapping site IC50 that we 
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measured (1.25 μM), a superficial site IC50 of ~30 μM was required to recreate the degree of 
partial trapping we observed experimentally (~17%).  While this superficial site IC50 value is 
lower than our experimentally measured value (79.1 μM), it is possible that our indirect protocol 
for measuring inhibition at the superficial site overestimated the IC50.  In addition, we were able 
to estimate only the IC50 of memantine for the superficial site based on binding that occurred 
when NMDA receptor channels were closed.  It is possible that the IC50 of memantine for the 
superficial site is lower when channels are open. 
2.5.3 Voltage dependence of trapping 
We attempted to vary the amount of memantine binding at the deep site, relative to the 
superficial site, by running the trapping protocol at various membrane voltages.  We 
hypothesized that depolarizing the membrane voltage would cause a greater increase in the IC50 
of memantine for the deep site than the IC50 for the superficial site, leading to greater memantine 
binding at the superficial site and less trapping.   Alternatively, hyperpolarizing the membrane 
voltage should favor deep site binding and greater memantine trapping.   
Memantine and ketamine trapping was significantly affected by membrane voltage.  
However, ketamine was more fully trapped than memantine at all voltages tested.  Ketamine’s 
lack of affinity for the superficial site would explain the lesser effect of membrane voltage on its 
trapping; however, the significant effect of voltage we measured may reflect a contribution of 
faster ketamine unbinding at more depolarized voltages (Table 1).  The unbinding time constants 
of memantine and ketamine were also significantly affected by membrane voltage.  Therefore, 
although these data are in agreement with our hypothesis, they leave open the possibility that 
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membrane voltage may have affected trapping because of affects on unbinding kinetics rather 
than competition between the superficial and deep sites.   
2.5.4 Superficial memantine binding site may overlap the external cation binding site of 
NR1/2A receptors 
We tested whether the superficial memantine binding site on NR1/2A receptors overlaps the 
binding site for external cations.  We lowered [ion]o 4-fold and tested whether or not memantine 
binding at the superficial site, as well as trapping, was affected.  Low [ion]o slightly lowered the 
deep site IC50 of memantine compared to the IC50 value measured in control [ion]o (Figure 9A).  
We found that lowering [ion]o significantly increased memantine binding at the superficial site, 
compared binding at that site in control solution, after wash durations of either 0.4, 1, and 3 s 
(Figure 9B).  Significant differences were not measured at longer wash durations because 
recovery from block was nearly complete in both conditions.  Consistent with our hypothesis, the 
decrease in binding of memantine at the superficial site, compared to binding at the deep site in 
low [ion]o was accompanied by a significant increase in fractional recovery (Figure 9C).  These 
data provide further support for a role of the superficial memantine binding site in partial 
trapping. 
Our finding that [ion]o affects memantine binding at the superficial site suggests there 
may be overlap between the binding site for extracellular cations and the superficial memantine 
binding site.  A region of the NR1 subunit located just after the C-terminal end of the M3 
transmembrane region has been demonstrated through mutational analysis to modulate Ca2+ 
influx through NMDA receptors (Watanabe et al., 2002).  A string of amino acids (DRPEER) 
with a net negative charge forms a region that binds Ca2+ through an electrostatic interaction.  It 
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is possible that the DRPEER site could contribute to the superficial site binding of positively 
charged memantine.  However, the DRPEER site is located outside of the voltage field of 
NMDA receptors (Sobolevsky et al., 2002).  Memantine binding to the superficial site is voltage-
dependent (Blanpied et al., 1997), which argues against the suggestion that the DRPEER site 
contributes to the superficial site.  However, it is possible that the DRPEER site is only part of 
the superficial memantine binding site and that other regions, located within the voltage field, 
also contribute this site. 
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3.0  MG2+ IMPARTS NMDA RECEPTOR SUBTYPE SELECTIVITY TO THE 
ALZHEIMER’S DRUG MEMANTINE 
3.1 ABSTRACT 
Research on memantine’s mechanism of action has focused on the NMDA receptor subtypes 
most highly expressed in adult cerebral cortex, NR1/2A and NR1/2B receptors (Cull-Candy and 
Leszkiewicz, 2004), and has largely ignored interactions with extracellular Mg2+ (Mg2+o).  Mg2+o 
is an endogenous NMDA receptor channel blocker that binds near memantine’s binding site 
(Kashiwagi et al., 2002; Chen and Lipton, 2005).  We report that a physiological concentration 
(1 mM) of Mg2+o at resting membrane potential decreased memantine inhibition of NR1/2A and 
NR1/2B receptors nearly 20-fold, but decreased memantine inhibition of the other principal 
NMDA receptor subtypes, NR1/2C and NR1/2D receptors, only ~3-fold.  As a result, therapeutic 
memantine concentrations should have negligible effects on NR1/2A or NR1/2B receptor 
activity but pronounced effects on NR1/2C and NR1/2D receptors.  We report similar results 
with the NMDA receptor channel blocker ketamine, a drug used to model schizophrenia (Krystal 
et al., 2003).  These results suggest that currently hypothesized mechanisms of memantine and 
ketamine action should be reconsidered.  NR1/2C and/or NR1/2D receptors play a more 
important role in cortical physiology and pathology than previously appreciated.  
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3.2 INTRODUCTION 
Functional NMDA receptors are composed of 4 subunits, and usually contain NR1 and one or 
more of the four NR2 (NR2A – NR2D) subunits (Dingledine et al., 1999).  NR2 subunit 
expression is developmentally and regionally regulated (Monyer et al., 1994; Cull-Candy and 
Leszkiewicz, 2004).  The identity of the NR2 subunit(s) in a NMDA receptor strongly influences 
receptor properties, including agonist and competitive antagonist affinities, deactivation kinetics, 
single-channel conductance, calcium (Ca2+) permeability, and characteristics of Mg2+o channel 
block (Dingledine et al., 1999; Cull-Candy and Leszkiewicz, 2004).  The high Ca2+ permeability 
of NMDA receptors and regulation of Ca2+ influx by voltage-dependent channel block by Mg2+o 
are properties of fundamental physiological and pathological importance.  Of particular 
relevance to the results presented here, NMDA receptor inhibition by Mg2+o is considerably 
weaker in NR1/2C and NR1/2D receptors than in NR1/2A or NR1/2B receptors (Kutsuwada et 
al., 1992; Monyer et al., 1994).  
Several drugs of clinical importance, including memantine, act by binding in the channel 
of NMDA receptors at a site that overlaps with the Mg2+o blocking site (Kashiwagi et al., 2002; 
Chen and Lipton, 2005).  Like Mg2+o, memantine block exhibits voltage dependence; the 
concentration of memantine that inhibits NMDA responses by 50% (the IC50) increases with 
depolarization (Rogawski and Wenk, 2003; Johnson and Kotermanski, 2006; Parsons et al., 
2007).  Memantine alleviates the cognitive decline associated with Alzheimer’s disease, and 
represents a major departure in Alzheimer’s disease therapy from previously-developed 
medications that enhance cholinergic transmission (Schmitt, 2005; Lipton, 2006).  Extensive 
evidence indicates that the therapeutic effects of memantine derive predominantly from NMDA 
  57
receptor inhibition (Rogawski and Wenk, 2003; Schmitt, 2005; Lipton, 2006; Parsons et al., 
2007). 
3.3 MATERIALS AND METHODS 
3.3.1 Cell culture and transfection 
Experiments were performed on the HEK293T mammalian cell line.  Cells were transfected 
using Lipofectamine (Invitrogen Corporation, Carlsbad, CA), as previously described (Qian and 
Johnson, 2006) with cDNA for the NR1-1a (GenBank accession number (ACCN) X63255, in 
pcDM8) subunit and either the NR2A (ACCN M91561, in pcDM8), NR2B (ACCN M91562, in 
pcDNA1), NR2C (ACCN M91563, in pcDNA1), or NR2D (ACCN L31612, in pcDM8) subunit.  
cDNA for enhanced Green Fluorescent Protein (eGFP) was co-transfected as a marker of 
successful transfection. 
3.3.2 Electrophysiology 
Whole-cell patch-clamp recordings were performed with an Axopatch-1D amplifier ~24 hours 
after transfection.  For experiments performed in 1 mM Mg2+o, cells with bright eGFP 
fluorescence (presumably associated with larger NMDA responses) were chosen.  Recording 
electrodes of 2 to 6 MΩ resistance were filled with an internal solution consisting of (in mM): 
125 CsCl, 10 BAPTA, and 10 HEPES, with pH adjusted to 7.2 ± 0.05 with CsOH and osmolality 
of 275 ± 10 mmol/kg.  Series resistance was compensated 80 to 90%.  
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External solutions consisted of (in mM): 140 NaCl, 2.8 KCl, 1 CaCl2, and 10 HEPES 
(and 1 MgCl2 when indicated), with pH adjusted to 7.2 ± 0.05 with NaOH and osmolality 
adjusted to 290 ± 10 mmol/kg with sucrose.  Solutions were applied to cells by a seven-barrel, 
gravity-fed fast perfusion system.  Concentration-inhibition data were measured in the 
continuous presence of either 0 or 1 mM Mg2+o during application of 1 mM glutamate and 100 
μM glycine (“agonists”) with serial application of 5 concentrations of either memantine or 
ketamine ranging from 0 to up to 1 mM (see Figures 10 and 11).  A subsequent agonist 
application always was made, and data were rejected if the steady-state response to agonists 
following blocker washout did not recover to at least 70% of the response to agonists that 
preceded blocker application.  Correction for the measured junction potential of -6 mV was 
applied to all data. 
3.3.3 Data analysis 
Data were low-pass filtered at 100 Hz and analyzed using Clampfit 9.2 (Axon Instruments, 
Union City, CA).  Current averages over a 500 msec time window were used to obtain values of 
baseline current and steady-state NMDA receptor-mediated current, without or with memantine, 
ketamine, and/or Mg2+o as indicated.  Concentration-inhibition curves were fit using the equation  
   IMem/ICon or IKet/ICon = 1/(1 + ([B] /IC50) nH)  
where IMem and IKet are steady state currents in agonists + blocker(s), ICon is steady-state current 
in agonists alone, [B] is the concentration of memantine or ketamine, and nH is the Hill 
coefficient. 
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3.4 RESULTS 
Identification of an inhibitory drug’s site(s) of action requires knowledge of its IC50 at potential 
targets under physiological conditions.  The median value of the many published measurements 
of memantine’s IC50 for NMDA receptors at voltages near rest is ~1 μM (Johnson and 
Kotermanski, 2006; Parsons et al., 2007).  Memantine has been found to exhibit only weak 
NMDA receptor subtype selectivity, with an IC50 for NR1/2A receptors ~2 to several-fold higher 
than for NR1/2B, NR1/2C, and NR1/2D receptors (Dravid et al., 2007; Parsons et al., 2007).  
Use of these data to evaluate memantine’s potential interactions with NMDA receptors under 
physiological conditions suffers from a potentially critical oversight: endogenous Mg2+ may 
compete with or otherwise affect memantine binding.  Previous estimates of memantine affinity, 
selectivity, and voltage dependence have been performed in the absence of Mg2+o, possibly 
because of difficulty in measuring memantine inhibition of the small NMDA responses observed 
in physiological Mg2+o.  However, evidence for overlap of memantine and Mg2+o binding sites 
(Kashiwagi et al., 2002; Chen and Lipton, 2005) and hindrance of memantine binding by Mg2+o 
(Sobolevsky et al., 1998) suggest that physiological Mg2+o could powerfully influence 
memantine inhibition of NMDA receptors.  If Mg2+o and memantine compete for binding in the 
channel, then the IC50 of memantine should increase in the presence of Mg2+o.  We therefore 
examined memantine inhibition of NMDA receptors in the presence of a physiological (1 mM) 
concentration of Mg2+o.  
We compared memantine inhibition of whole-cell currents recorded at −66 mV from 
HEK293T cells transfected with cDNAs encoding the NR1 and either the NR2A, NR2B, NR2C, 
or NR2D subunits in 0 and 1 mM Mg2+o.  NMDA responses were activated with saturating 
concentrations of glutamate (1 mM) and glycine (100 μM) to avoid possible agonist 
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concentration dependence of memantine inhibition (Lipton, 2006) (but see Parsons et al., 2007).  
Results of experiments in 0 Mg2+o demonstrated that memantine exhibits little NMDA receptor 
subtype selectivity, consistent with previous measurements.  Memantine IC50s for all NMDA 
receptor subtypes were between 0.5 and 1 μM (Figure10A, B, Table 2), with the IC50 for 
NR1/2A receptors slightly higher than for other receptor subtypes.  
 
 
 
A B 
C D 
 
Figure 10.  Effects of Mg2+o and NMDA receptor subunit composition on memantine inhibition.  
A and B, Overlay of NR1/2A (black) and NR1/2D (red) receptor current traces recorded from 
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transfected HEK293T cells in 0 Mg2+o (A) and 1 mM Mg2+o (C) during application of the 
indicated concentrations of memantine.  Peak inward NR1/2A receptor currents here and in 
Figure 11 are truncated.  Similar experiments were performed with NR1/2B and NR1/2C 
receptors (examples not shown).  B and D, Memantine concentration-inhibition curves recorded 
in 0 Mg2+o (B) and 1 mM Mg2+o (D) from HEK293T cells transfected with the indicated NMDA 
receptor subtype.  Memantine shows almost no subunit selectivity in 0 Mg2+o (B) but is selective 
for NR1/2C and NR1/2D receptors in 1 mM Mg2+o (D).  Grey shaded areas represent estimated 
free extracellular memantine concentration range (0.5 – 1 μM) during typical therapeutic 
treatment (Parsons et al., 2007).   
 
 
Under conditions similar to those used here, 1 mM Mg2+o inhibits responses of NR1/2A 
and NR1/2B receptors by ~95%, and responses of NR1/2C and NR1/2D receptors by ~80% 
(Clarke & Johnson, unpublished observations and Monyer et al., 1994).  Use of transfected 
HEK293T cells with large NMDA receptor-mediated currents nevertheless permitted accurate 
measurement of memantine concentration-inhibition curves in 1 mM Mg2+o.  The memantine 
IC50 was influenced strongly, and in a subtype-selective manner, by 1 mM Mg2+o (Figure 10C, 
D, Table 2): memantine concentration-inhibition curves were right-shifted by factors of 16.8 
(NR1/2A), 18.2 (NR1/2B), 3.1 (NR1/2C), and 3.3 (NR1/2D).  As a result, in 1 mM Mg2+o, 
memantine acquires a 5.9- to 8.3-fold selectivity for NR1/2C and NR1/2D receptors over 
NR1/2A and NR1/2B receptors.  
We also investigated the effects of Mg2+o on NMDA receptor inhibition by ketamine, 
another channel blocker of broad clinical and pathological significance that exhibits kinetics and 
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IC50s similar to memantine’s.  Ketamine is an important tool in schizophrenia research because it 
is psychotomimetic in healthy adults, exacerbates symptoms in schizophrenics (Krystal et al., 
2003), and is commonly used to generate animal models of schizophrenia (Moghaddam and 
Jackson, 2003).  Despite its psychotomimetic properties in adult humans, ketamine is used as a 
general anesthetic in children and animals, and demonstrates potential in the treatment of other 
conditions, including neuropathic pain (Annetta et al., 2005).  Ketamine has been reported to be 
largely unselective among NMDA receptor subtypes (Yamakura et al., 1993; Dravid et al., 
2007).  However, as with memantine, nearly all studies of the IC50 of ketamine and subtype 
selectivity have been performed in 0 Mg2+o; when interactions have been examined, NMDA 
receptor inhibition by ketamine has been reported both to be both reduced (MacDonald et al., 
1991) and augmented (Liu et al., 2001) by Mg2+o.   
Our ketamine IC50 measurements in 0 and 1 mM Mg2+o are shown in Figure 11 and Table 
2.  The effects of 1 mM Mg2+o on ketamine inhibition strongly resembled the effects on 
memantine inhibition: ketamine concentration-inhibition curves were right-shifted by factors of 
16.2 (NR1/2A), 16.4 (NR1/2B), 2.3 (NR1/2C), and 3.6 (NR1/2D).  Thus, the powerful effects of 
Mg2+o are not specific to memantine, a conclusion also supported by previous data indicating that 
the ketamine analog phencyclidine interacts competitively with Mg2+o when inhibiting NMDA 
responses (Lerma et al., 1991).  Because of the structural dissimilarity of memantine and 
ketamine, the results presented here suggest that NMDA receptor channel-blocking drugs in 
general interact competitively with Mg2+o.   
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 A B 
C D 
 
Figure 11.  Effects of Mg2+o and NMDA receptor subunit composition on ketamine inhibition.  
A and C, Overlay of NR1/2A (black) and NR1/2D (red) receptor current traces recorded from 
transfected HEK293T cells in 0 Mg2+o (A) and in 1 mM Mg2+o (C) during application of the 
indicated concentrations of (+/−) ketamine.  Similar experiments were performed with NR1/2B 
and NR1/2C receptors (examples not shown).  B and D, Ketamine concentration-inhibition 
curves recorded in 0 Mg2+o (B) and in 1 mM Mg2+o (D) from HEK293T cells transfected with the 
indicated NMDA receptor subtype. 
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Table 2.  Effect of Mg2+o on IC50s for memantine and ketamine inhibition of NMDA receptors.     
 
NMDA Receptor Subtype 
 
NR1/2A NR1/2B NR1/2C NR1/2D 
Drug [Mg
2+]o 
(mM) IC50 IC50
Ratio 
2A
2B 
IC50
Ratio 
2A
2C 
IC50
Ratio 
2A
2D 
0 0.80 ± 0.07 0.57 ± 0.09 1.40 0.52 ± 0.02 1.54 0.54 ± 0.06 1.48 
Memantine 
1 13.4 ± 1.3 10.4 ± 0.4 1.29 1.61 ± 0.06 8.32 1.76 ± 0.06 7.61 
0 0.33 ± 0.01 0.31 ± 0.02 1.06 0.51 ± 0.01 0.65 0.83 ± 0.02 0.40 
Ketamine 
1 5.35 ± 0.34 5.08 ± 0.02 1.05 1.18 ± 0.04 4.53 2.95 ± 0.02 1.81 
 
All IC50 values are in μM.  IC50 values measured using concentration-inhibition curves are given 
as mean ± SEM, and are based on measurements from 3-4 cells for each condition.  Each ratio is 
the IC50 for NR1/2A receptors divided by the IC50 for the indicated NMDA receptor subtype. 
 
 
3.5 DISCUSSION 
The above results show a powerful effect of Mg2+o on the IC50, selectivity of clinically relevant 
NMDA receptor channel blockers.  The IC50 increases take place in a critical concentration 
range.  The free extracellular memantine concentration in the brain of patients following typical 
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treatment regimes is estimated to be ~0.5 – 1 μM (Parsons et al., 2007).  The similarity of the 
therapeutic concentration of memantine to its IC50 for NMDA receptors measured in 0 Mg2+o has 
been critical in identifying NMDA receptors as the site of memantine action.  Because of 
memantine’s weak NMDA receptor subtype selectivity in 0 Mg2+o (Dravid et al., 2007; Parsons 
et al., 2007) and the high expression of NR2A and NR2B subunits in cortex (Cull-Candy and 
Leszkiewicz, 2004), research generally has focused on memantine interactions with NR2A 
and/or NR2B-containing receptors (Blanpied et al., 1997; Kashiwagi et al., 2002; Chen and 
Lipton, 2005; Parsons et al., 2007).  It has also been suggested that the therapeutic utility of 
memantine may be related to its weak selectivity for NR2C and NR2D containing receptors 
observed in 0 Mg2+o (Rogawski and Wenk, 2003; David et al., 2006).  Our data show that in 
physiological Mg2+o and at voltages near rest, the memantine IC50 for NR1/2A and NR1/2B 
receptors is over an order of magnitude higher than therapeutic brain concentrations (Figure 10, 
Table 2).  1 mM Mg2+o has a far weaker effect on the IC50 of memantine (as well as ketamine, 
and probably other channel blockers) for NR1/2C and NR1/2D receptors, for two reasons: first, 
because Mg2+o inhibits NR1/2C and NR1/2D receptors with relatively high IC50s; and second, 
because of incomplete competition between Mg2+o and memantine (or ketamine) at NR1/2C and 
NR1/2D receptors.  These data suggest that NR2C and/or NR2D containing NMDA receptors are 
likely sites of pharmacological memantine action.  Memantine also inhibits other receptors with 
low IC50s, including nicotinic acetylcholine receptors (nAChRs) (Aracava et al., 2005; Parsons et 
al., 2007).  Inhibition of nAChRs appears unlikely to be the principal basis of memantine’s 
therapeutic utility in Alzheimer’s disease (Johnson and Kotermanski, 2006; Parsons et al., 2007), 
since Alzheimer’s disease treatments other than memantine are aimed at augmenting cholinergic 
transmission.  
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The clinical effects of memantine and ketamine suggest that preferential inhibition of 
NR2C and/or NR2D containing NMDA receptors can strongly impact cognitive function.  NR2C 
and NR2D subunits are expressed in the adult mammalian hippocampus and cortex, brain 
regions extensively involved in Alzheimer’s disease and schizophrenia, although at lower levels 
than NR2A or NR2B subunits.  Pathological activation, by long exposure to low levels of 
glutamate, of extrasynaptic NR2D containing receptors could raise the overall synaptic noise, 
making detection of physiologically relevant signals difficult (Parsons et al., 2007).  A possible 
consequence of inhibition of NR2D containing NMDA receptors is preferential reduction of 
tonic NMDA receptor-mediated pyramidal cell currents, thereby decreasing synaptic noise (Le 
Meur et al., 2007).  Alternatively, inhibition of NR2D containing receptors could selectively 
reduce excitation of the subset of inhibitory neurons that highly express NR2D (Monyer et al., 
1994), resulting in disinhibition of excitatory neurons, thereby enhancing physiologically 
relevant signals.  In Alzheimer’s disease, amyloid-β accumulation (especially in excitatory 
pyramidal neurons (D'Andrea and Nagele, 2006) can cause internalization of NMDA receptors 
(Snyder et al., 2005) and preferential loss in cortex of excitatory terminals (Bell and Claudio 
Cuello, 2006).  Memantine could partially counterbalance these effects by preferentially 
inhibiting interneuronal NMDA receptors; if this suggestion is correct, then more selective 
inhibition of NR1/2D receptors may hold therapeutic promise.  The clinical utility of memantine 
may be enhanced by its inhibition of α-7 nAChRs (Aracava et al., 2005), which participate in 
amyloid-β-induced NMDA receptor internalization (Snyder et al., 2005).  Ketamine shows a 
similar (although weaker) preferential inhibition of NR1/2C and NR1/2D receptors, which 
suggests more complex subtype selectivity.  Nevertheless, ketamine’s selective action at NR2C 
containing receptors at normal resting potential also may lead to cortical disinhibition, a process 
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hypothesized to be responsible for ketamine’s ability to induce a schizophrenia-like psychotic 
state (Greene, 2001).  These ideas emphasize the importance of understanding the roles played 
by NR2C and NR2D subunits in cortical function, and the mechanisms that underlie the diverse 
clinical actions of NMDA receptor channel blockers.  
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4.0  DIRECT COMPARISON OF THE LOCOMOTOR AND COGNITIVE EFFECTS 
OF THE NMDA RECEPTOR ANTAGONISTS MEMANTINE AND KETAMINE IN 
RATS 
4.1 ABSTRACT 
Conflicting results have been reported on the extent of behavioral effects elicited by some 
NMDA receptor antagonists in rats, which may be attributable in part to differences in drug 
administration protocols, as well as animal strain, age, and sex.  Many studies tested the 
antagonist’s effects at only one time delay after administration of the drug, ignoring the 
pharmacokinetic differences that exist among many of the drugs tested.  We directly compared, 
in adult male Sprague-Dawley rats, the effects of two drugs that inhibit NMDA receptor activity 
with similar affinity and kinetics, but very different pharmacokinetic profiles.  Intraperitoneal 
injections of either 0, 5, 10, 20, or 40 mg/kg doses of either memantine or of ketamine were 
administered and effects on behavior in an activity monitor and in a spontaneous alternation task 
were measured.  To examine how pharmacokinetic differences between these two drugs affect 
behavior, animals were tested either 15 or 45 min after drug administration.  Both memantine 
and ketamine decreased ambulatory activity and rearings when the context of the testing 
environment was novel, with memantine’s effect being significantly different from saline-treated 
controls even at the lowest dose tested.  Once rats were familiarized with the testing 
environment, memantine, but not ketamine increased ambulatory activity at the high doses 
tested.  Regardless of the context of the environment, the effects of ketamine on behavior in an 
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activity monitor were more affected by testing delay than those of memantine.  The lowest dose 
of memantine or ketamine tended to increase spatial working memory as assessed in the 
spontaneous alternation task compared to controls at the shorter testing delay.  However, the 
higher doses of either drug impaired performance  in this task, which did not depend on the time 
of testing after drug administration.  Furthermore, memantine, but not ketamine, elicited 
perseverative behavior; this effect was more pronounced when animals were tested 45 min after 
drug administration.  Overall, our results indicate that the behavioral effects of memantine 
tended to be left-shifted and longer lasting compared to those of ketamine, consistent with the 
longer pharmacokinetics of memantine compared to that of ketamine. 
4.2 INTRODUCTION 
The clinical use of NMDA receptor inhibitors has been limited because they tend to induce 
symptoms similar to the disease of schizophrenia (Palmer, 2001; Lipton, 2004b).  Ketamine, in 
particular, reliably reproduces the positive, negative, and cognitive symptoms of schizophrenia in 
healthy adults as well as exacerbating symptoms in already afflicted individuals (Cromhout, 
2003).   Although not widely used clinically, ketamine has been critical in furthering our 
understanding of the underlying pathology of schizophrenia.  The NMDA receptor antagonist 
memantine, which inhibits NMDA receptor activity with similar affinity and kinetics as 
ketamine (Parsons et al., 1993; Mealing et al., 1999), lacks the psychotomimetic side-effects 
associated with many other NMDA antagonists and has been approved as a treatment for late-
stages of moderate to severe Alzheimer’s disease (Witt et al., 2004). 
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The behavioral effects of memantine versus ketamine in rats have been examined 
previously (Hetzler and Wautlet, 1985; Danysz et al., 1994; Barnes et al., 1996; Creeley et al., 
2006; Koros et al., 2007); however, direct comparisons between these studies are difficult 
because of differences in rat strain, age, sex (Wilson et al., 2007), time of testing after drug 
administration, as well as route of drug administration.  Subanaesthetic doses (up to 100 mg/kg) 
of ketamine administered to rats was reported to increase locomotor activity, decrease rearing, 
cause deficits in spatial working memory, induce stereotypic behavior, and decrease social 
behavior (Hetzler and Wautlet, 1985; Danysz et al., 1994; Koros et al., 2007).  Effects similar to 
those of ketamine were observed in rats administered memantine, although the extent of the 
effects were less pronounced and required higher doses (Danysz et al., 1994; Koros et al., 2007).  
Moreover, contrary to the results mentioned above, data from Creeley et al. (2006) show that 
memantine produces severe locomotor deficits at neuroprotective doses (20 mg/kg, i.p.).  Creeley 
et al. (2006) furthermore found that memantine administration at doses lower than those needed 
for neuroprotection (5 and 10 mg/kg, i.p.) causes locomotor and memory retention deficits.   
A key aspect of memantine and ketamine that has not been investigated in previous 
studies is the difference in pharmacokinetics that exists between them.  Whereas the distribution 
half-life in rat after injection of ketamine is ~1 min (Cohen et al., 1973; White et al., 1982; 
Annetta et al., 2005), for memantine it is ~1 h (Spanagel et al., 1994; Parsons et al., 1999).  In 
previous studies, behavioral testing was conducted at only one time point after drug 
administration (Danysz et al., 1994; Koros et al., 2007).  The differences in pharmacokinetic 
profile between memantine and ketamine should result in different cerebrospinal fluid (CSF) 
concentrations of the drugs at any one time after administration, which, in turn, might give rise to 
differences in the behavioral effects of the two drugs.    
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The focus of the present study was to test whether the differences in pharmacokinetics 
between memantine and ketamine are a primary source of the difference in behavioral effects 
elicited by the drugs.  We tested this by assessing and directly comparing the effects in rat, of 
varying doses (0 - 40 mg/kg) of memantine and of ketamine on exploratory behavior in an 
activity monitor and on spatial working memory in the spontaneous alternation task, at either 15 
min or 45 min after drug administration.   
4.3 MATERIALS AND METHODS 
4.3.1 Animals 
Protocols were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee.  Adult male Sprague-Dawley rats weighing 250-275 g (Hilltop Labs, Scottdale, PA, 
USA) at the beginning of the study were used.  Rats were single-housed and allowed 24-72 hr to 
acclimatize to the housing facility before the start of daily handling.  The housing facility was 
maintained at a 12/12 hr light-dark cycle (lights on 0700) with a temperature of 22 ± 1 ºC and a 
humidity level of 45 ± 5 %.  Animals were given free access to standard rat food and tap water.   
4.3.2 Drugs and drug administration 
Memantine hydrochloride (Sigma-Aldrich Co., St. Louis, USA; Fisher Scientific, Pittsburgh, 
USA) and ketamine hydrochloride (Sigma-Aldrich Co., St. Louis, USA) were dissolved in sterile 
physiological saline (0.9 % NaCl) and administered intraperitoneally (i.p.) at a volume of 2 
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ml/kg.  Solutions were refrigerated and used within 3 weeks after preparation.  Solutions were 
allowed to warm to room temperature before administration. 
4.3.3 Experimental procedures 
All handling and testing was performed in the Rodent Behavior Analysis Core facility of the 
University of Pittsburgh.  Testing was conducted during the light phase of the light-dark cycle.  
Rats were handled in the housing facility for 5-7 min each for 3 d before the start of behavioral 
testing.  At the end of the handling period rats were assigned to one of 10 drug conditions: 
memantine vehicle (0.9% NaCl saline); one of 4 doses of memantine (either 5, 10, 20, or 40 
mg/kg); ketamine vehicle (0.9% NaCl saline); or one of 4 doses of ketamine (either 5, 10, 20, or 
40 mg/kg).  In addition, rats were assigned to one of two delays between drug administration and 
testing (either 15 min or 45 min).  The experimenter was blind to the drug condition until 
completion of the study.  Each animal was assigned to only one drug dose and one test delay 
time.  All rats were tested in both behavioral paradigms (described below), and the order of 
testing was consistent across all animals (exploratory activity test followed by spontaneous 
alternation task).   Rats were tested in each behavioral paradigm once and allowed 48 h to 
recover before the next testing paradigm.  Rats were euthanized by CO2 following completion of 
testing. 
4.3.4 Exploratory activity test 
Exploratory activity was monitored the day after completion of the 3 day handling period.  Rats 
were injected with drug in a holding room separate from the housing and testing rooms and 
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placed back in their respective holding cages until testing.  Animals were tested individually, and 
were naive to the testing room until the start of the 30 min testing session.  Ambient illumination 
of the testing room was ~10 lux.  Testing began when rats were placed in the center of a square-
shaped activity monitor (42.5 cm x 42.5 cm x 30 cm; Med-Associates Inc., St. Albans, VT).  The 
experimenter was not present in the room during testing.  The animals’ horizontal and vertical 
movements were monitored with the aid of infra-red light beams and detectors located along the 
sides of the walls of the test arena.  Beam interruptions were analyzed offline with the aid of 
Med-Associates proprietary software.  After testing, rats were returned to their respective home 
cages and returned to the housing facility, and the test arena was wiped clean with Quatracide 
before testing the next subject. 
4.3.5 Spontaneous alternation task 
Rats were injected in the holding room and returned to their holding cages until testing, as 
described above.  Ambient illumination of the testing room was ~30 lux.  The testing apparatus 
was a plus-shaped maze (arm dimensions: 47.5 cm x 9.8 cm x 20.3 cm) with a square center 
platform (9.8 cm x 9.8 cm) (Lafayette Instruments, Lafayette, IN).  Animals were tested 
individually.  Testing began when rats were placed in the center of the maze.  Rats were allowed 
to explore freely the maze for 15 min.  Arm entries (order and frequency) were monitored and 
analyzed with the use of an overhead digital camera and tracking software 
(Actimetrics/Coulbourn Instruments, Whitehall, PA).  The experimenter was not present in the 
room during testing.  After testing, rats were returned to their respective home cages and to the 
housing facility, and the maze was wiped clean with Quatracide before testing the next subject.  
An alternation was defined as an entry into four different arms during five consecutive arm 
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entries.  Alternation scores were calculated by dividing the total number of alternations made by 
an animal by the total number of possible alternations (i.e., the total number of overlapping 
quintuplets).  This value was multiplied by 100 to yield percent alternation.  Perseveration was 
defined as an entry into the same arm twice during three consecutive arm entries.  Perseveration 
scores were calculated by dividing the total number of perseverations made by an animal by the 
total number of possible perseverations (i.e., the total number of overlapping triplets).  This value 
was multiplied by 100 to yield percent perseveration.   
4.3.6 Statistical analysis 
Data are presented as group means ± standard errors of the mean (SEM).  To address the 
questions of interest to us, we evaluated dose effects for each drug and delay separately using 
one-way analyses of variance (ANOVA’s) followed by post-hoc Dunnett tests to determine for 
which doses the effect differed significantly from saline.  We evaluated differences between 
delays for each drug and dose separately using Student’s t-tests for independent groups.  
Similarly, we evaluated differences between drugs for each dose and delay separately using 
Student’s t-tests for independent groups.  For all analyses, the significance level was set to p ≤ 
0.05. 
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4.4 RESULTS 
4.4.1 Memantine effects on behavior in the exploratory activity test 
Animal behavior was assessed by monitoring rats’ performance in a 30 min exploratory activity 
test.  The rats’ behavioral profile changed markedly over the 30 min testing session (Figure 12A, 
B), especially the behavior of saline-treated animals.  Therefore, we focused our attention on the 
first 5 min of testing (Figure 12C), when the context of the testing environment was novel, and 
the last 5 min of testing (Figure 12D), when rats were relatively familiar with the test 
environment.   
Memantine administered (i.p. injection) either 15 min or 45 min before testing resulted in 
a significant dose-dependent decrease in ambulatory distance during the first 5 min of testing [15 
min, F(4,36) = 20.11, p ≤ 0.01; 45 min, F(4,36) = 5.85, p < 0.01].  Post-hoc tests revealed that in 
animals tested 15 min after memantine administration, every dose of memantine caused a 
significant decrease in ambulatory distance, whereas in animals tested 45 min after memantine 
administration, only doses of 10 mg/kg or higher caused a significant reduction in distance 
travelled during the first 5 min (p’s < 0.01, Figure 12C).  Although there was a trend for 
ambulatory distance to be reduced less when animals were tested 45 min after memantine 
administration, the effect of delay was not significant at any of the doses tested (all p’s > 0.05). 
During the last 5 min of the 30 min test, when animals had become familiar with the test 
environment, the ambulatory distance travelled by saline animals was markedly reduced, as 
expected (compare Figure 12D with 12C).  In contrast, animals treated with higher doses of 
memantine became more active; although this effect was observed only in animals tested 15 min 
after memantine administration.  Whereas the dose effect was significant for the 15 min groups 
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[F(4,36) = 8.89, p < 0.01], it failed to reach significance in animals tested 45 min after drug 
administration (p > 0.05).  Post-hoc tests revealed that at the early test delay, animals injected 
with 40 mg/kg memantine travelled significantly farther than saline controls during the last 5 min 
of the test (p < 0.01, Figure 12D).  None of the delay effects were significant (all p’s > 0.05). 
 
 
 
A B 
C D 
 
Figure 12.  Effect of memantine on ambulatory distance in the exploratory activity test.  A and 
B, Activity was averaged across 5 min intervals for the entire 30 min of testing.  Memantine was 
administered either 15 min (A) or 45 min (B) before testing.  The effect of time between 
memantine administration and testing on ambulatory distance in a novel and familiar 
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environment was assessed by examining the first (C) and last (D) 5 min of activity in the activity 
monitor, respectively.  The results are displayed as means (cm/5 min) ± SEM of 9 (saline) or 8 
(memantine doses) rats.  # significantly (p ≤ 0.05) different from respective saline controls 
(Dunnett test). 
 
 
The loss in ambulatory distance we observed as a result of memantine administration in 
the first 5 min of activity testing cannot simply be attributed to a reduction in travel speed.  
Because, animals tested 15 min after memantine administration showed no significant effect of 
dose on travel speed.  In animals tested 45 min after memantine administration, a significant 
dose-dependent decrease in travel speed was observed [F(4,36) = 4.83, p < 0.01] because animals 
treated with the two highest doses tended to travel more slowly compared to saline-treated 
animals (20 mg/kg, p < 0.01; 40 mg/kg, p < 0.05, Table 3).  Delay had no significant effect on 
travel speed (all p’s >0.05).  Memantine administration had no significant effect on travel speed 
during the last 5 min of open-field testing regardless of the delay before testing (p’s > 0.05, 
Table 3).  Taken together, these results suggest that the observed changes in distance travelled 
are not the result of a drug effect on travel speed.  Rather, the reduction in ambulatory distance 
appears to be due to a reduction in the amount of time engaged in ambulatory activity.   
 
The results are displayed as means (cm/sec) ± SEM of 9 (saline) or 8 (memantine doses) rats.  # significantly (p ≤ 0.05) different from 
respective saline controls (Dunnett test).  
1st 5 min Last 5 min  
Saline 5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg Saline 5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg
15 min 
Delay 
66.2 ± 
4.0 
45.2 ± 
3.9 
117.4 ± 
26.1 
57.1 ± 
19.1 
69.1 ± 
17.1 
73.9 ± 
5.8 
55.6 ± 
15.4 
47.1 ± 
14.7 
35.5 ± 
6.2 
60.1 ± 
7.8 
45 min 
Delay 
65.3 ± 
2.5 
61.1 ± 
3.8 
51.3 ± 
3.5 
41.2 ± 
5.6   # 
49.1 ± 
6.1   # 
83.0 ± 
10.3 
60.9 ± 
10.1 
57.6 ± 
10.9 
45.7 ± 
8.1 
56.8 ± 
8.4 
  
Table 3.  Effect of memantine on average velocity of ambulation in the exploratory activity test 
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Much like we observed for ambulatory distance, the saline-treated animals showed a 
marked decrease in the number of times they reared over the course of the 30 min testing session 
(Figure 13A, B).  Administration of memantine either 15 min or 45 min before testing resulted in 
a significant dose dependent decrease in rearings during the first 5 min of testing [15 min, F(4,36) 
= 42.98, p ≤ 0.01; 45 min, F(4,36) = 20.60, p < 0.01].  Post-hoc tests revealed that at both delays 
every dose of memantine tested caused a significant decrease in the number of rearings (p’s < 
0.01, Figure 13C).  Although there was a trend for rearings to be reduced less when animals were 
tested 45 min, compared to 15 min, after memantine administration, the effect of delay was only 
significant at the highest dose tested (p < 0.05). 
Rearing behavior was also reduced for saline-treated animals during the last 5 min of 
testing (Figure 13D).  A significant dose-dependent decrease in rearings was observed for both 
the 15 min and 45 min delay groups [15 min, F(4,36) = 21.22, p < 0.01; 45 min, F(4,36) = 8.35, p < 
0.01].  Post-hoc tests revealed that at the early test delay, all memantine doses tested caused a 
significant decrease in the number of rearings compared to saline controls during the last 5 min 
of the test (all p’s < 0.01, Figure 13D).  When animals were tested 45 min after memantine 
administration, all but the lowest dose caused a significant decreased in the number of rearings 
(p’s < 0.01).  The drug effect on rearing during the last 5 min of the test was not sensitive to test 
delay (all p’s > 0.05). 
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Figure 13.  Effect of memantine on number of rearings in the exploratory activity test.  A and B, 
Activity was averaged across 5 min intervals for the entire 30 min of testing.  Memantine was 
administered either 15 min (A) or 45 min (B) before testing.  The effect of time between 
memantine administration and testing on number of rearings in a novel and familiar environment 
was assessed by examining the first (C) and the last (D) 5 min of activity in the activity monitor, 
respectively.  The results are displayed as means (counts/5 min) ± SEM of 9 (saline) or 8 
(memantine doses) rats.  # significantly (p ≤ 0.05) different from respective saline controls 
(Dunnett test).  * significantly (p ≤ 0.05) different across delay (Student’s t-test). 
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4.4.2 Memantine effect on behavior in the spontaneous alternation task 
The effect of memantine on spatial working memory was assessed by monitoring rats’ 
performance in a 15 min spontaneous alternation task.  The spontaneous alternation task tests 
spatial working memory by taking advantage of a rats’ natural tendency to explore its 
environment.  As long as spatial working memory is not impaired, rats’ will tend to explore the 
different arms of the plus-maze before re-entering an arm that has already been explored.  
Administration of memantine either 15 min or 45 min before testing resulted in a significant 
dose-dependent decrease in animals performances in the alternation task [15 min, F(4,36) = 5.97, p 
≤ 0.01; 45 min, F(4,36) = 15.68, p < 0.01].  Post-hoc tests revealed that in both delay groups, 
animals performances in the task were significantly reduced compared to saline controls when 
memantine was administered at either 20 or 40 mg/kg (all p’s < 0.05, Figure 14A).  No 
significant delay effect was observed at any of the doses tested (all p’s > 0.05). 
Upon analysis of the spontaneous alternation data, we noticed that some animals 
exhibited distinctly repetitive (perseverative) behavior, visiting the same two arms over and over.  
Therefore, we decided to analyze the data for this perseverative behavior (see Methods).  
Memantine caused a dose-dependent increase in this behavior whether administered 15 min 
[F(4,36) = 4.37, p < 0.01] or 45 min [F(4,36) = 12.72, p < 0.01] before testing.  Post-hoc analyses 
showed that the 20 mg/kg group was significantly different from saline-treated animals at either 
testing delay, whereas 40 mg/kg group of memantine elicited a significant increase in 
perseverative behavior only at the longer delay between drug administration and testing (all p’s < 
0.01, Figure 14B).  Accordingly, a delay effect was observed only at highest dose tested (p < 
0.05). 
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C 
 
Figure 14.  Effect of memantine on behavior in the spontaneous alternation task.  A – C,  The 
effect of memantine administered either 15 min or 45 min before testing on % alternation (A), % 
perseveration (B), and number of arm entries (C) in the plus-maze task.  The results are 
displayed as means (%) ± SEM of 9 (saline) or 8 (memantine doses) rats.  # significantly (p ≤ 
0.05) different from respective saline controls (Dunnett test).  * significantly (p ≤ 0.05) different 
across delay (Student’s t-test). 
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The finding that perseverative behavior increased at the higher doses of memantine 
renders it unlikely that the decrease in alternation behavior at those doses was the result of a 
reduction in arm entries by animals that received memantine.  Nevertheless, to examine a 
possible contribution of an overall decrease in maze exploration to the reduction in alternation, 
the total number of arm entries during the task was monitored and compared across conditions.  
The results revealed that the number of arm entries was reduced only by the highest dose of 
memantine tested and only at the 15 min delay between drug administration and testing [F(4,36) = 
6.27, p < 0.01].  A significant effect of delay on arm entries was observed for the 40 mg/kg dose 
of memantine (p < 0.05, Figure 14C).  Thus, it cannot be ruled out that the decrease in alternation 
in the group that received 40 mg/kg of memantine and was tested 15 min after drug 
administration was not attributable, at least in part, to a decrease in arm entries. 
4.4.3 Ketamine effects on behavior in the exploratory activity test 
Similar to what we observed in animals treated with memantine (Figure 12A, B), the rats’ 
behavioral profile changed markedly over the 30 min of testing in the activity monitor (Figure 
15A, B).  As previously, we focused our attention on the first 5 min, when the context was novel 
(Figure 15C), and the last 5 min of testing, when the test context was familiar (Figure 15D).  
Ketamine administered (i.p. injection) either 15 min or 45 min before testing resulted in a 
significant dose-dependent decrease in ambulatory distance during the first 5 min of testing [15 
min, F(4,36) = 7.02, p ≤ 0.01; 45 min, F(4,36) = 8.81, p < 0.01].  Post-hoc tests revealed that in 
animals tested 15 min after ketamine administration, all but the lowest dose tested caused a 
significant decrease in ambulatory distance (all p’s < 0.05).  In contrast, for animals tested 45 
min after ketamine administration, only doses of 20 mg/kg or higher caused a significant 
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reduction in distance travelled during the first 5 min (p’s < 0.05, Figure 15C).  Ambulatory 
distance tended to be reduced less when animals were tested 45 min after ketamine 
administration; however, the effect of delay was only significant at the 5 mg/kg dose and the 20 
mg/kg doses (p’s < 0.05). 
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C D 
 
Figure 15.  Effect of ketamine on ambulatory distance in the exploratory activity test.  A and B,  
Activity was averaged across 5 min intervals over the entire 30 min of testing.  Ketamine was 
administered either 15 min (A) or 45 min (B) before testing.  The effect of time between 
ketamine administration and testing on ambulatory distance in a novel and a familiar 
  85
environment was assessed by examining the first (C) and last (D) 5 min of activity in the activity 
monitor, respectively.  The results are displayed as means (cm/5 min) ± SEM of 9 (saline) or 8 
(ketamine doses) rats.  # significantly (p ≤ 0.05) different from respective saline controls 
(Dunnett test).  * significantly (p ≤ 0.05) different across delay (Student’s t-test).   
 
 
As expected, ambulatory distance was reduced for saline-treated animals during the last 5 
min of the 30 min test, when animals are familiarized with the test environment (Figure 15D).  In 
contrast to memantine, ketamine had no effect on ambulatory distance traveled during the last 5 
min in animals treated 15 min before testing (p > 0.05) and caused a significant dose-dependent 
decrease in animals tested 45 min after drug administration [F(4,36) = 2.98, p < 0.05].  The results 
of post-hoc tests revealed that animals that received 20 mg/kg or 40 mg/kg of ketamine travelled 
significantly less than saline controls when tested 45 min after ketamine administration (p ≤ 0.05, 
Figure 15D).  Delay had a significant affect on ambulatory behavior during the last 5 min only in 
the groups that received 10 mg/kg of ketamine, with animals tested at the longer delay travelling 
further than animals tested at the short delay (p < 0.05). 
Similar to our observations with memantine, the decrease in ambulatory distance as a 
result of ketamine administration during the first 5 min in the activity monitor cannot be 
attributed to a reduction in travel speed.  Regardless of the delay between drug administration 
and the beginning of testing, no significant effect of dose or delay on ambulation speed were 
observed (p’s > 0.05, Table 4).  The decrease in ambulatory distance we observed as a result of 
ketamine administration during the last 5 min in the activity monitor also cannot simply be 
attributed to reduced travel speed.  Although animals tested 15 min after ketamine administration 
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did show a significant dose-dependent effect on average velocity during the last 5 min [F(4,36) = 
4.22, p < .01].  However, only the 20 mg/kg dose group was significantly reduced from saline-
treated controls (p < 0.05, Table 4), a group that showed no significant effect on ambulatory 
distance.  No significant dose effects were observed for the 45 min delay groups (p > 0.05).  No 
significance of testing delay was measured at any dose (p’s > 0.05). 
Measurements of the number of rearings over the 30 min test session showed that 
rearings markedly changed over the testing session (Figure 16A, B).  Much like memantine 
(Figure 13A, B), the administration of ketamine was associated with a large reduction in rearing 
behavior regardless of whether animals were tested 15 min or 45 min after drug administration 
[15 min, F(4,36) = 20.52, p ≤ 0.01; 45 min, F(4,36) = 18.51, p < 0.01].  Post-hoc tests revealed that 
at both delays, each but the lowest dose of ketamine tested here caused a significant decrease in 
rearing behavior (p’s < 0.01, Figure 16C).  Rearings tended to be reduced less when animals 
were tested 45 min after ketamine administration; however, the effect of delay was significant 
only for the 5 mg/kg and 20 mg/kg doses (p < 0.05). 
Ketamine also caused a significant reduction in rearing behavior during the last 5 min of 
the 30 min test in animals tested 15 min as well as animals tested 45 min after drug 
administration [15 min, F(4,36) = 15.21, p < 0.01; 45 min, F(4,36) = 7.06, p < 0.01].  The results of 
post-hoc tests revealed that at the early test delay, all but the lowest ketamine dose tested 
significantly decreased number of rearings compared to saline controls during the last 5 min of 
the test (all p’s < 0.05, Figure 16D).  In contrast, when tested 45 min after ketamine 
administration, only the highest dose tested significantly decreased number of rearings (p’s < 
0.01).  Delay effects were significant only for the 20 mg/kg dose (p < 0.05). 
 
The results are displayed as means (cm/sec) ± SEM of 9 (saline) or 8 (ketamine doses) rats.  # significantly (p ≤ 0.05) different from 
respective saline controls (Dunnett test). 
1st 5 min Last 5 min  
Saline 5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg Saline 5 mg/kg 10 mg/kg 20 mg/kg 40 mg/kg 
15 min 
Delay 
66.0 ± 
3.6 
55.8 ± 
1.9 
64.2 ± 
10.4 
40.1 ± 
13.9 
48.1 ± 
14.7 
62.7 ± 
2.9 
69.3 ± 
5.5 
45.9 ± 
14.6 
24.6 ± 
10.1   # 
38.7 ± 
7.0 
45 min 
Delay 
61.8 ± 
4.6 
60.0 ± 
2.4 
57.3 ± 
3.6 
62.0 ± 
4.6 
50.9 ± 
13.2 
59.8 ± 
5.4 
51.0 ± 
9.4 
62.3 ± 
9.6 
42.6 ± 
11.2 
34.4 ± 
18.8 
  
Table 4.  Effect of ketamine on average velocity of ambulation in the exploratory activity test 
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Figure 16.  Effect of ketamine on number of rearings in the exploratory activity test.  A and B, 
Activity was averaged across 5 min intervals over the entire 30 min of testing.  Ketamine was 
administered either 15 min (A) or 45 min (B) before testing.  The effect of time between 
ketamine administration and testing on rearings in a novel or familiar environment was assessed 
by examining the first (C) and last (D) 5 min of activity in the activity monitor, respectively.  
The results are displayed as means (counts/5 min) ± SEM of 9 (saline) or 8 (ketamine doses) rats.  
# significantly (p ≤ 0.05) different from respective saline controls (Dunnett test).  * significantly 
(p ≤ 0.05) different across delay (Student’s t-test).   
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 4.4.4 Ketamine effects on behavior in the spontaneous alternation task 
Ketamine effects on spatial working memory were assessed by monitoring rats’ performance in a 
spontaneous alternation task.  Ketamine administration either 15 min or 45 min before testing on 
the plus-maze resulted in a significant dose-dependent decrease in alternation behavior [15 min, 
F(4,36) = 4.02, p ≤ 0.01; 45 min, F(4,36) = 4.06, p < 0.01].  Post-hoc tests showed that ketamine 
produced a significant reduction in alternation behavior from saline control levels only at the 
highest dose tested but this reduction was observed at both test delays (p < 0.05, Figure 17A).  
No significant delay effect was observed at any of the doses tested (all p’s > 0.05). 
Administration of ketamine either 15 min or 45 min before testing did not significantly 
affect perseverative behavior (p’s > 0.05, Figure 17B).  The total number of arm entries also was 
not affected when animals were tested 15 min after ketamine administration (p > 0.05).  
However, when animals were tested 45 min after drug administration, ketamine caused a 
significant decrease [F(4,36) = 8.85, p < 0.01], which was restricted to the two highest doses tested 
(20 mg/kg and 40 mg/kg, p’s < 0.01, Figure 17C).  We observed no significant delay effects on 
the total number of arm entries as a result of the administration of ketamine (all p’s > 0.05).  Our 
findings that the highest dose of ketamine caused a reduction in alternation behavior at both test 
delays but a reduction in arm entries only at the long delay further support our claim that the 
drug-associated decrease in alternation behavior cannot readily be explained in terms of a drug-
induced reduction in arm entries. 
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Figure 17.  Effect of ketamine on behavior in the spontaneous alternation task.  A – C,  The 
effect of ketamine administered either15 min or 45 min before testing on % alternation (A), % 
perseveration (B), and number of arm entries (C) in the plus-maze task.  The results are 
displayed as means (%) ± SEM of 9 (saline) or 8 (ketamine doses) rats.  # significantly (p ≤ 0.05) 
different from respective saline controls (Dunnett test).  
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4.4.5 Comparison of the effects of memantine and ketamine on behavior in the 
exploratory activity test 
The effects of memantine and ketamine on the tested behaviors were directly compared by 
subtracting each individual animal’s score from the average of the saline controls.  Drug-induced 
effects were analyzed separately for each test delay after drug administration.  Furthermore, as 
previously, attention was focused on the first 5 min and last 5 min of the test, when the context 
of the testing environment was novel and familiar, respectively. 
These comparisons revealed that, generally, the suppressive effect of memantine and 
ketamine on ambulation during the first 5 min of the exploratory activity test were more 
pronounced after administration of memantine than of ketamine.  This trend was statistically 
significant at the lowest dose when the drugs were administered 15 min before testing (p < 0.05, 
Figure 18A), and at the second lowest dose (10 mg/kg) when they were administered 45 min 
before testing (p < 0.05, Figure 18B).  The high doses (20 and 40 mg/kg) of both drugs decreased 
ambulatory distance to the same extant, possibly as a result of a floor effect (achieved at the 10 
mg/kg dose for memantine).  Overall the data suggest that the effects of memantine on 
ambulatory distance in a novel environment are left-shifted compared to those of ketamine.    
Memantine and ketamine had more diverse effects on ambulatory distance during the last 
5 min of exploratory activity testing.  The higher doses of memantine increased ambulatory 
distance, especially at the shorter testing delay, whereas no such effect was observed with 
ketamine.  Accordingly, the effect of memantine and ketamine on ambulatory behavior during 
the last 5 min was found to differ significantly from one another at the two highest doses (20 and 
40 mg/kg) when administered 15 min before testing (p’s < 0.01, Figure 18C) and at the highest 
dose (40 mg/kg) when administered 45 min before testing (p < 0.01, Figure 18D).  
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Figure 18.  Comparison of memantine’s and ketamine’s effect on ambulatory distance in the 
exploratory activity test.  The effect of memantine or ketamine administered either 15 min (A, C) 
or 45 min (B, D) before testing on ambulatory distance was analyzed during the first 5 min of the 
test , when the environment was novel (A, B), and the last 5 min of the test when the 
environment was familiar (C, D).  The results are displayed as means (cm/5 min) ± SEM of 18 
(saline) or 8 (drug doses) rats.  & significant (p ≤ 0.05) difference from corresponding drug dose 
(Student’s t-test). 
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 Similar to the pattern of effect on ambulation, memantine revealed to cause a greater 
reduction in rearing behavior than did ketamine, and this effect was observed at both testing 
delays as well as during the first and the last 5 min of testing.  During the first 5 min of testing 
this trend was significant only at the lowest dose tested (5 mg/kg) when the drugs were 
administered 15 min before testing (p < 0.05, Figure 19A), possibly due to a maximum effect at 
all higher doses.  When administered 45 min before testing, memantine caused a significantly 
greater reduction in rearing compared to ketamine at all doses tested, except that at the highest 
dose tested, a small increase in rearing from the suppressed level by memantine treated animals 
resulted in a reversal in relation between the drug effects that revealed also to be statistically 
significant (all p’s < 0.05, Figure 19B).  The greater suppressive effect of memantine, compared 
to ketamine, on rearing also was evident during the last 5 min of the exploratory activity test.  
However, at the highest dose tested here, the relationship between the drugs again was reversed.  
Thus, when administered 15 min before testing, memantine caused a greater reduction in rearing 
during the last 5 min at 5 mg/kg and 10 mg/kg, but less of a reduction at 40 mg/kg (all p’s ≤ 
0.05, Figure 19C).  When administered 45 min before testing, memantine caused a greater 
reduction in rearing at 10 mg/kg and 20 mg/kg, whereas the relationship was reversed at 40 
mg/kg (all p’s < 0.05, Figure 19D).  Like we observed during the first 5 min of testing, 
memantine’s effects on rearings during the last 5 min appeared to be left-shifted compared to the 
effects of ketamine, and a trend that was more obvious at the longer test delay because 
ketamine’s effect appeared to begin wearing off, especially at the lower doses. 
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Figure 19.  Comparison of memantine’s and ketamine’s effects on number of rearings in the 
exploratory activity test.  The effect of memantine or ketamine administered either 15 min (A, C) 
or 45 min (B, D) before testing on number of rearings was analyzed for the first 5 min of the test, 
when the environment was novel (A, B) and for the last 5 min of the test when the environment 
was familiar (C, D).  The results are displayed as means (counts/5 min) ± SEM of 18 (saline) or 
8 (drug doses) rats.  & significant (p ≤ 0.05) difference from corresponding drug dose (Student’s 
t-test). 
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4.4.6 Comparison of the effects of memantine and ketamine on behavior in the 
spontaneous alternation task 
Overall, a similar effect on alternation behavior was observed following administration of either 
memantine or ketamine.  Only the high doses of either drug decreased rats’ performance in 
spatial alternation regardless of the time between drug administration and testing (Figure 20A, 
B).  Although memantine tended to be more effective than ketamine at reducing performance in 
the alternation task at both delays, significant differences between drugs was achieved only for 
the 20 mg/kg dose administered 45 min before testing (p < 0.05, Figure 20B).  In Contrast, the 
effects of memantine or ketamine on perseverative behavior in this task were markedly different.  
Animals tested 15 min after administration of 20 mg/kg of memantine showed a significant 
increase in the occurrence of perseverative behavior compared to ketamine (p ≤ 0.05, Figure 
20C).  When testing began 45 min after dug administration, a significantly greater increase in 
perseverative behavior was observed in memantine-treated animals’ compared to ketamine-
treated animals’ at both the 20 mg/kg and the 40 mg/kg dose (p < 0.01, Figure 20D). 
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Figure 20.  Comparison of memantine’s and ketamine’s effect on behavior in the spontaneous 
alternation task.  Depicted is the effect of either memantine or ketamine administered either 15 
min (A, C) or 45 min (B, D) before testing on % alternation (A, B) and % perseveration (C, D) in 
the plus-maze.  The results are displayed as means (%) ± SEM of 18 (saline) or 8 (drug doses) 
rats.  & significantly (p ≤ 0.05) different from corresponding drug dose (Student’s t-test). 
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4.4.7 Comparison of the effects of memantine and ketamine on general behavior in the 
exploratory activity test 
The time rats spent in four distinct types of activity (resting, ambulating, non-travel movement 
(limb or head movements made while the animals’ body was stationary), and rearing) during the 
30 min in the activity monitor were measured.  These values were transformed into percent time 
spent in each activity over the entire 30 min of testing.  These data reveal that the rats spent a 
majority of the test session resting regardless of the drug administered or the time of testing after 
administration (Figure 21).  The percent time rats rested was dramatically increased by 
administration of memantine or ketamine even at the lowest dose (5 mg/kg) tested.  The increase 
in resting time resulting from administration of memantine or ketamine was closely associated 
with a decrease in time spent rearing.  The percent time spent ambulating as well as in non-travel 
movement was not greatly affected by administration of memantine or ketamine at the doses 
tested.   
Comparing the effects of memantine and ketamine on time spent in the activities 
measured at either delay demonstrates that, at the lower doses (5 and 10 mg/kg) tested, 
memantine’s effects appear left-shifted compared to those of ketamine.  This left-shift appears 
more prominent when rats were tested 45 min (Figure 21B, D) rather than 15 min (Figure 21A, 
C) after drug administration, seemingly due to a greater reduction of the drug effects among 
ketamine-treated animals.  Another distinct difference between the drugs in their effect on 
activity in the activity monitor was that the higher doses (20 and 40 mg/kg) of memantine caused 
an increase in relative time spent ambulating and engaging in non-travel movement, whereas this 
trend did not develop among ketamine-treated animals. 
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A C 
B D 
 
Figure 21.  Comparison of memantine’s and ketamine’s effect on general behavior in the 
exploratory activity test.  Depicted is the effect of either memantine (A, B) or ketamine (C, D) 
administered either 15 min (A, C) or 45 min (B, D) before testing on the % time spent in various 
activities (resting, ambulating, non-travel movement, and rearing) in the activity monitor.  The 
results are displayed as the percent of total time spent in each activity for 9 (saline) or 8 (drug 
dose) rats. 
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4.5 DISCUSSION 
We administered varying doses of either memantine or ketamine via i.p. injection either 15 min 
or 45 min before examining behavior in the exploratory activity test and, on a separate occasion, 
behavior in the spontaneous alternation task.  We used these two time delays between drug 
administration and testing to assess the effect of previously reported pharmacokinetic differences 
between these two drugs (Cohen et al., 1973; White et al., 1982; Spanagel et al., 1994; Parsons et 
al., 1999; Cromhout, 2003; Annetta et al., 2005) on behavior.  We found that administration of 
memantine induced similar, yet more pronounced and longer lasting behavioral changes than did 
ketamine.  In addition, memantine, at the higher doses, evoked some behavioral trends not 
observed in animals treated with similarly high doses of ketamine. 
4.5.1 Memantine and ketamine effects on behavior in the exploratory activity test 
At the doses tested, and at both testing delays, memantine (Figure 12C, 18A, B) and ketamine 
(Figure 15C, 18A, B) dose-dependently reduced ambulatory behavior during the first 5 min of 
exploratory activity testing compared to saline controls.  The effects of memantine appeared to 
be less affected by the delay before testing, whereas ketamine’s effects tended to wane over the 
longer test delay.  However, in contrast to our observations of a reduction in ambulatory activity, 
previous studies (Hetzler and Wautlet, 1985; Danysz et al., 1994; Koros et al., 2007) found that 
these two NMDA receptor antagonists tended to increase locomotor behavior.  A possible 
explanation for the apparent discrepancy, is that the test environment was novel to the rats in our 
study, whereas rats had been habituated to the test environment in the previous studies (Hetzler 
and Wautlet, 1985; Danysz et al., 1994; Koros et al., 2007).  Thus, it is possible that under 
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conditions of a novel environment, both memantine and ketamine have a suppressive effect on 
ambulatory behavior.  In contrast, under conditions of a familiar environment, the NMDA 
receptor antagonists tend to increase ambulatory behavior.  Consistent with this possibility, we 
found, similar to the previous reports (Danysz et al., 1994; Koros et al., 2007), that during the 
last 5 min of the exploratory activity test, when the ambulatory behavior of saline-treated 
animals was markedly reduced because of habituation to the test environment, animals treated 
with the highest dose of memantine we tested, 40 mg/kg, exhibited a significant increase in 
ambulatory distance compared to saline controls (Figure 12D, 18C, D).  Ketamine, on the other 
hand, never elicited an increase in ambulatory distance during the last 5 min of exploratory 
activity testing at the doses we tested (Figure 15D, 18C, D).  These results appear to conflict with 
the previous reports that ketamine induces increased locomotor activity (Hetzler and Wautlet, 
1985; Danysz et al., 1994); however, it should be noted that in these previous studies, the doses 
of ketamine that elicited an increase in locomotor activity were higher (> 50 mg/kg) than those 
tested here.  One study (Koros et al., 2007) did report a significant increase in locomotor activity 
in rats administered a dose of ketamine (s.c.) as low as 8 mg/kg.  The divergent effects elicited 
by memantine and ketamine on ambulatory activity in a familiar environment suggest there may 
be a fundamental difference in the actions of these two drugs when administered at higher doses. 
Memantine and ketamine, dose-dependently decreased rearing behavior in the 
exploratory activity test, regardless of the degree of novelty of the test environment or the testing 
delay.  Previous studies also found that these drugs decrease rearing (Danysz et al., 1994; Koros 
et al., 2007).  Our results demonstrate that, although similar, memantine’s effect on rearing 
behavior is more pronounced and longer lasting than is ketamine’s effect (Figure 19). 
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The left-shift of memantine’s effects on general activity in the activity monitor compared 
to ketamine’s effects at the low-to-moderate doses (5 and 10 mg/kg) tested here and the wearing 
off of ketamine’s effects at the longer delay are clearly demonstrated in Figure 21.  This figure 
also demonstrates the divergent effects of the higher drug doses (20 and 40 mg/kg) tested.   
4.5.2 Memantine and ketamine effects in the spontaneous alternation task 
Animals were tested in the spontaneous alternation task to asses the effects of memantine and 
ketamine on cognitive functioning, specifically on spatial working memory.  A previous study by 
Jackson et al. (2004) demonstrated that administration of a low dose of another, higher affinity, 
NMDA receptor antagonist, MK-801 (0.01 mg/kg, i.p.), increased performance in this task; 
however, higher doses (≥ 0.05 mg/kg) significantly impaired performance compared to saline-
treated controls.   Here, we did not observe a significant increase in alternation behavior upon 
administration of either memantine or ketamine, although a slight trend toward enhanced 
alternation emerged at the lowest dose tested (5 mg/kg).  It is possible that a lower dose of 
memantine or ketamine could have resulted in a statistically significant enhancement of 
performance in the alternation task.  Higher doses of memantine and ketamine tested in our study 
tended to reduce spontaneous alternation, consistent with what Jackson et al. (2004) observed 
with MK-801.  Although memantine’s effects in this task tended to be more prominent than 
ketamine’s, this trend generally was not statistically significant (Figure 20A, B). 
The effects of memantine and ketamine on perseverative behavior measured with the 
plus-maze reveals a fundamental difference between the actions of these two drugs.  At the doses 
tested, ketamine had no affect on perseverative behavior (Figure 17B), whereas memantine 
caused a dramatic increase in perseverative behavior at the higher dosestested (Figure 14B).   
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4.5.3 Examination of the behavioral effects elicited by memantine and ketamine 
The main site of action of both memantine and ketamine is thought to be NMDA receptors 
(Bormann, 1989; Kornhuber et al., 1989; Yamamura et al., 1990; Witt et al., 2004).  It is 
surprising that memantine has more profound behavioral effects than ketamine, given that 
electrophysiological data suggest that ketamine has a higher affinity for NMDA receptors 
(Parsons et al., 1993; Parsons et al., 1995; Parsons et al., 1996; Mealing et al., 1999).  Although 
ketamine is a more effective inhibitor of NMDA receptor-mediated responses than memantine, 
the pharmacokinetics of memantine were found to be much slower than those of ketamine 
(White et al., 1982; Spanagel et al., 1994; Cromhout, 2003).  The slower pharmacokinetics of 
memantine make it likely that a given dose of memantine will accumulate in the cerebrospinal 
fluid (CSF) at a higher concentration than does the same dose of ketamine.  The higher drug 
concentration in the CSF will allow memantine to more effectively inhibit NMDA receptor-
mediated responses, explaining the left-shift of the behavioral effects we observed when 
comparing the effects of the lower doses (5 and 10 mg/kg) of the two drugs.  The slower 
pharmacokinetics of memantine could also explain why memantine’s effects, when assessed 45 
min after drug administration, tended to be comparable to those observed 15 min after drug 
administration.  In the case of ketamine, on the other hand, significant differences between the 
two test delays emerged more frequently, likely due to more rapid wearing off of the drug’s 
effects.  
The divergent effects of the higher doses of memantine and ketamine tested here suggest 
one of two possibilities; 1) the effects of memantine and ketamine on some behaviors are best 
represented by a U-shaped curve, and/or 2) memantine and ketamine differentially affect other 
neurotransmitter systems at the higher doses tested.  Some of the data gathered in this study 
  103
(such as locomotor activity) suggest a U-shaped dose-response curve for memantine.  It is 
possible that a similar trend would be observed with ketamine as well had we tested yet higher 
doses.  Consistent with this possibility, previous studies (Hetzler and Wautlet, 1985; Danysz et 
al., 1994) measuring ketamine’s effect on locomotor activity noted an increase in activity at 
doses of 50 mg/kg and higher.  Regardless of the shape of the dose-response curves, it is highly 
likely that effects on other neurotransmitter systems, in addition to an effect on NMDA 
receptors, occur at the higher doses tested here.  Both memantine and ketamine affect other 
neurotransmitter systems at concentrations comparable to those measured for NMDA receptor 
inhibition (Parsons et al., 1995; Blanpied et al., 1997; Danysz et al., 1997; Sobolevsky and 
Koshelev, 1998; Sobolevsky et al., 1998; Mealing et al., 1999; Coates and Flood, 2001; Rammes 
et al., 2001; Kashiwagi et al., 2002; Maskell et al., 2003; Aracava et al., 2005; Seeman et al., 
2005; Chen and Lipton, 2006; Seeman et al., 2008).   
Compared to each other, both memantine and ketamine demonstrate a similar affinity for 
NMDA receptors regardless of subunit composition (Yamakura et al., 1993; Bresink et al., 1996; 
Parsons et al., 1999).  Therefore, it is unlikely that the different effects of the high doses of these 
drugs reported here are a result of differential inhibition at NMDA receptor subtypes.  Another 
receptor that has been hypothesized to play a role in psychotic behavior is the functional high-
affinity state of the D2 dopamine receptor (D2High) (Seeman et al., 2006).  However, action at the 
D2High receptor is also an unlikely explanation for the difference in behavioral effects of high 
doses of memantine versus ketamine, because both drugs are high-affinity agonists at D2High 
receptors (Seeman et al., 2005; Seeman et al., 2008).  The affinity of these drugs for D2High 
receptors is comparable to that for NMDA receptors; therefore, any effect on behavior as a result 
of the drugs’ actions on D2High receptors should not be limited to just one of the two drugs.   
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It is unclear how effects at other neurotransmitter systems may have contributed to the 
divergent behavioral responses we observed at the highest doses of the drugs tested in this study.  
In summary, our results suggest that pharmacokinetics can have an important effect on the type 
and extent of behavioral changes elicited by a given dose of drug.  Investigators need to be aware 
of pharmacokinetic differences between drugs when comparing behavioral effects measured at a 
single time point after administration. 
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5.0  GENERAL DISCUSSION 
Proper NMDA receptor functioning is crucial for the accurate transmission of synaptic signals 
within the vertebrate CNS.  Alterations in NMDA receptor-mediated neurotransmission via 
pharmacological agents, injury, or disease can lead to debilitating effects on behavior and 
cognition.  Attempts at pharmacologically restoring normal NMDA receptor function due to 
insult or disease have been met with varied success.  The research presented in this dissertation 
was performed in an attempt to understand the success and failure of two mechanistically similar 
NMDA receptor antagonists, memantine and ketamine, as therapeutic agents.  
5.1 INTEGRATION OF BEHAVIORAL AND ELECTROPHYSIOLOGICAL 
FINDINGS 
The behavioral and cognitive effects of memantine and ketamine were directly assessed in adult 
male Sprague-Dawley rats.  Overall, our results suggest that memantine and ketamine, at low-to-
moderate doses, induce similar behavioral and cognitive effects in rat; however, the effects of 
memantine tended to be more pronounced at a given dose.  The behavioral and cognitive changes 
measured with low-to-moderate doses of memantine appeared to be less affected by the time of 
testing after drug administration than ketamine.  At higher doses, however, memantine and 
ketamine had divergent effects, which may reflect actions of these drugs at CNS targets other 
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than NMDA receptors.  In order to integrate our behavioral findings with our 
electrophysiological findings we will ignore the actions of these drugs at alternate targets until 
later.   
We measured memantine’s and ketamine’s ability to inhibit activity of recombinant 
NMDA receptors.  We report that memantine is slightly less effective than ketamine at inhibiting 
NMDA receptor activity in the absence of Mg2+o.  We also report that NR2 subunit composition 
did not greatly affect inhibition by either drug.   
The reported overlap of the binding site of memantine and ketamine with that for Mg2+o 
(Sobolevsky et al., 1998; Kashiwagi et al., 2002) suggests that competition is likely to occur 
between these drugs and endogenous Mg2+o.  To better understand the actions of memantine and 
ketamine on NMDA receptor activity in the CNS we measured the ability of these drugs to 
inhibit NMDA receptor-mediated responses near resting potential in the presence of a 
physiologically relevant concentration (1 mM) of Mg2+o.  The presence of 1 mM Mg2+o 
decreased the ability of memantine and ketamine to inhibit NMDA receptors composed of the 
NR1 and any NR2 subunit.  However, the decrease in inhibitory ability was more prominent for 
NR1/2A or NR1/2B receptors than for NR1/2C or NR1/2D receptors.  In the presence of 
physiological Mg2+o, ketamine was still slightly more effective than memantine at inhibiting 
NMDA receptor activity at all NR2 subunits except at receptors composed of the NR1/2D 
subunit.  Our results suggest that physiological Mg2+o imparts NMDA receptor subunit 
specificity to the inhibitory effects of memantine and ketamine; however, the shift in IC50 values 
were similar for the two drugs.  Because of the prevalence of the NR2A and NR2B subunit in the 
cortex, a majority of research has examined memantine’s and ketamine’s interaction with 
NMDA receptors composed these NR2 subunits.  An important finding of our results is that 
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NR2C and/or NR2D containing NMDA receptors may be more involved in physiology and 
disease than previously appreciated.  These findings alone are unlikely, however, to explain the 
varying behavioral and cognitive effects that we observed at high doses, since we observed 
relatively small differences in the subunit specificity of memantine compared to ketamine.   
Another aspect of NMDA receptor inhibition by memantine and ketamine that we 
examined was the degree to which these drugs become trapped within the channels of receptors 
that have closed and unbound agonist.  It has been reported (Blanpied et al., 1997; Chen and 
Lipton, 1997; Sobolevsky and Koshelev, 1998; Sobolevsky et al., 1998; Mealing et al., 1999), 
and our results agree, that ketamine is more fully trapped within closed NMDA receptor 
channels than memantine.  We found evidence supporting the hypothesis (Figure 6) that the 
differences in trapping of memantine and ketamine is the result of memantine interacting with 
NR1/2A receptors at two binding sites, a deep trapping site (shared by both drugs) and a 
superficial non-trapping site.  The partial trapping of memantine should allow some recovery 
from inhibition between successive synaptic signals.  Whereas the more complete trapping of 
ketamine should result in no recovery from inhibition between synaptic events, leading to greater 
inhibition of NMDA receptor mediated activity.  It remains unclear whether NR2 subunit 
composition affects the degree of trapping of memantine or ketamine, especially at NR1/2C or 
NR1/2D receptors.  
At first glance our behavioral and electrophysiological findings appear contradictory.  
How can it be that, at the same dose, greater behavioral and cognitive effects were elicited by 
memantine which is generally less effective at inhibiting NMDA receptor activity (their main 
site of action) than ketamine?  A likely explanation lies in the pharmacokinetic differences 
between memantine and ketamine.  In humans the elimination half-life of ketamine (~2.5 h) is 
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much faster than for memantine (60-80 h) (White et al., 1982; Spanagel et al., 1994; Parsons et 
al., 1999; Cromhout, 2003; Annetta et al., 2005; Johnson and Kotermanski, 2006).  If this 
difference in elimination half-life is similar in rat, then a higher concentration of memantine than 
ketamine should build up in the brain after administration of a given dose.  Thus, a greater 
concentration of memantine will be present in the CNS to inhibit NMDA receptor activity than 
ketamine.  Our observation that the behavioral effects induced by memantine are less affected by 
the time of testing after administration than ketamine is in agreement with this line of thinking.   
The more profound behavioral and cognitive effects of memantine, compared to 
ketamine, at lower doses may be attributable to its longer pharmacokinetic profile.  However, the 
longer elimination half-life of memantine allows for a therapeutic dose to be practically 
administered as a once-a-day oral tablet.  The faster elimination half-life of ketamine would 
likely require multiple daily dosings to achieve a comparable steady state concentration of drug 
in the CSF.  Thus, the slower pharmacokinetics of memantine compared to ketamine is likely to 
contribute to its greater therapeutic benefit.  It should be noted that long pharmacokinetics is not 
always desirable in a clinical situation.  While useful for prolonged or chronic treatments, the 
longer pharmacokinetics of a drug makes quick changes in plasma levels more difficult.  The fast 
pharmacokinetics of ketamine is likely to contribute to its usefulness as an anesthetic, where 
tight control of drug plasma levels is a necessity.   
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5.2 POSSIBLE CONSEQUENCES OF NR2C AND/OR NR2D RECEPTOR 
INHIBITION 
As demonstrated in this document, the NMDA receptor antagonists memantine and ketamine are 
more effective at inhibiting NR1/2C or NR1/2D receptors, than NR1/2A or NR1/2B receptors, in 
the presence of physiological Mg2+o.  This finding suggests the need for a greater understanding 
of the role NR2C and NR2D containing receptors play in the functioning of the CNS.   
In adults, the NR2C subunit of NMDA receptors exhibits higher levels of expression, 
compared to other brain regions only in the cerebellar granule cells (Monyer et al., 1992; Ishii et 
al., 1993; Monyer et al., 1994; Wenzel et al., 1996; Cull-Candy et al., 2001).  It is unclear how 
NMDA receptor antagonism of NR2C containing receptors in the cerebellum may contribute to 
the behavioral and cognitive consequences of memantine or ketamine administration.  
Antagonism at NR2C containing receptors and disruption of cerebellar activity would likely 
result in ataxia, which appeared to occur at the higher doses of memantine and ketamine tested 
but was not measured.  The effects of memantine and ketamine on cerebellar functioning could 
be measured by testing rat performance on a rotorod.  However, our interest is more on the 
behavioral effects of these drugs which are likely mediated by forebrain, where NR2C 
expression is low (Monyer et al., 1992; Ishii et al., 1993; Monyer et al., 1994; Wenzel et al., 
1996; Cull-Candy et al., 2001).  Therefore, this discussion will focus more on the effects of 
antagonism at NR2D receptors. 
Although levels are lower than for NR2A or NR2B containing receptors, NR2D 
containing receptors are present extrasynaptically in the adult cortex and on inhibitory 
interneurons in the hippocampus (Monyer et al., 1994; Akbarian et al., 1996; Standaert et al., 
1996; Wenzel et al., 1996; Dunah et al., 1998; Fleidervish et al., 1998; Munoz et al., 1999; 
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Thompson et al., 2002; Lozovaya et al., 2004; Binshtok et al., 2006; Karavanova et al., 2007).  In 
situations where relatively low CSF concentrations of memantine or ketamine favor inhibition of 
NR2D containing receptors over NR2A or NR2B, excitatory neurotransmission may be 
enhanced.  Extrasynaptic NR2D containing receptors, which are less inhibited by Mg2+o than 
those containing NR2A or NR2B, should be more active in pathologically compromised cortical 
neurons.  This is likely to increase the baseline level of activity of those neurons and a resultant 
decrease in the ability to detect physiologically relevant signals (Parsons et al., 2007).  
Preferential inhibition of extrasynaptic NMDA receptors that contain the NR2D subunit could 
help to decrease the heightened level of background noise hypothesized to occur in Alzheimer’s 
disease (Parsons et al., 2007).  Furthermore, preferential inhibition of NR2D containing receptors 
expressed on interneurons would decrease interneuron firing and as a result may enhance 
physiologically relevant signals (Krystal et al., 2003).  This proposed mechanism of preventing 
pathological activity while preserving, or possibly enhancing, physiological stimuli may explain 
the beneficial cognitive effects of relatively low CSF concentrations memantine.  Memantine’s 
slightly better ability to inhibit NR2D containing receptors than ketamine may contribute to the 
greater therapeutic utility of memantine.  Related to this idea, our behavioral results 
demonstrated a slight but insignificant enhancement of rats’ performance in a spatial working 
memory task after acute administration of a dose (5 mg/kg, i.p., Figure 20A) considered to result 
in a therapeutically relevant brain concentration of memantine (Parsons et al., 2007).  However, 
we also observed this increase in spatial working memory with a corresponding dose of 
ketamine.  It is possible that an even lower dose may have enhanced animals’ performance in the 
task even further.  Although this is consistent with the beneficial actions of memantine in 
humans (Parsons et al., 1999; Kilpatrick and Tilbrook, 2002; Witt et al., 2004), it is not 
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consistent with the actions of ketamine, which does not appear to enhance cognitive functioning 
in humans (Krystal et al., 1999a; Krystal et al., 2003). 
When the brain concentration of memantine or ketamine reaches a level sufficient to 
achieve significant inhibition at all NMDA receptor subtypes, NMDA receptor-mediated 
transmission may become sufficiently disrupted to resemble the hypofunction associated with 
schizophrenia (Aghajanian and Marek, 2000; Coyle et al., 2003), thereby inducing 
schizophrenic-like symptoms (Newcomer et al., 1999; Aghajanian and Marek, 2000; Coyle et al., 
2003; Northoff et al., 2005).  NMDA receptor antagonism has been shown to preferentially 
decrease activity of inhibitory neurons, leading to disinhibition (Greene, 2001).  Possible 
explanations for the increased sensitivity of interneurons to NMDA receptor inhibition, 
compared to excitatory pyramidal neurons, include differential NMDA receptor subtype 
expression (Monyer et al., 1994; Akbarian et al., 1996; Standaert et al., 1996; Wenzel et al., 
1996; Dunah et al., 1998; Fleidervish et al., 1998; Munoz et al., 1999; Greene, 2001; Thompson 
et al., 2002; Lozovaya et al., 2004; Binshtok et al., 2006; Karavanova et al., 2007), and greater 
excitatory drive to interneurons that could lead to less Mg2+o block of NMDA receptors 
(Povysheva et al., 2006).  A result of NMDA receptor antagonist-induced disinhibition is an 
increase in glutamate release (Moghaddam and Jackson, 2003).  The higher baseline level of 
glutamate (Krystal et al., 1999a; Krystal et al., 2003) that results from disinhibition of 
interneuron activity would be likely to make it more difficult for physiological stimuli to be 
detected.  The decreased ability to detect physiologically relevant stimuli, as a result of increased 
glutamate release in the cortex, may contribute to the observed decrease (hypofrontality) in 
performance of schizophrenic patients (Weinberger and Berman, 1996), as well as in individuals 
administered ketamine (Northoff et al., 2005), on tasks mediated by the prefrontal cortex.  
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5.3 POSSIBLE BENEFITS OF PARTIAL VERSUS FULL TRAPPING 
A possible contributor to the greater tolerability of low doses of memantine compared to 
ketamine in humans may be the difference in degree of trapping by NMDA receptors.  The 
partial trapping of memantine should allow some (~17 %) synaptic receptors to recover from 
block between successive releases of glutamate from presynaptic terminals.  This should allow 
for greater detection of subsequent physiologically relevant signals, while still effectively 
decreasing the baseline level of NMDA receptor activity at the postsynaptic neuron, thereby 
presumably preserving (although likely decreasing) physiological activity.  The mechanism of 
partial trapping effectively results in greater inhibition of chronically active NMDA receptors 
than those activated by brief pulses of agonists.  The partial trapping of memantine suggests that 
it can never completely block NMDA receptor response to successive presynaptic releases of 
glutamate.  It is unclear if partial trapping of memantine occurs at NR2C or NR2D containing 
receptors, or how partial trapping by NMDA receptors composed of these subunits may 
contribute to the tolerability of memantine. 
The more complete trapping of ketamine will likely not allow for recovery of receptors 
from the blocked state between successive presynaptic releases of glutamate.  This should result 
in a greater depression of NMDA receptor mediated transmission including a more profound 
disturbance of physiological activity, which may underlie ketamine’s lower tolerability in 
humans compared to memantine.  It should be noted that at high concentrations of memantine 
and ketamine, NMDA receptor activity should be so disrupted that any beneficial effect of partial 
trapping could be lost.  Examining differences in trapping of memantine and ketamine at NR2C 
or NR2D containing receptors, where we show they are likely to exert their action in the CNS, 
may help further our understanding of the therapeutic and behavioral effects of these drugs. 
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5.4 POSSIBLE EFFECTS ON OTHER NEUROTRANSMITTER SYSTEMS 
We found that physiological Mg2+o decreased the ability of memantine or ketamine to inhibit 
activity at their main site of action, NMDA receptors, near resting membrane potentials.  Thus, 
although NMDA receptor mediated transmission is still likely to be greatly affected by 
memantine or ketamine, the actions of these drugs are not as NMDA receptor-specific as 
previously imagined.   
Memantine has been reported to inhibit serotonin (5-HT3) (Danysz et al., 1997; Rammes 
et al., 2001; Chen and Lipton, 2006) and nicotinic acetylcholine (nACh) (α7) receptors (Maskell 
et al., 2003; Aracava et al., 2005; Chen and Lipton, 2006), as well as having agonist actions at 
dopamine receptors (D2High) (Seeman et al., 2008).  These actions of memantine have been 
reported to occur at concentrations comparable those that inhibit NMDA receptors.  Ketamine 
demonstrates antagonistic effects at α7 nACh receptors (Coates and Flood, 2001) and agonist 
effects at D2High dopamine receptors (Seeman et al., 2005) at concentrations comparable to those 
reported for memantine.   
Of particular importance to schizophrenia are the actions of memantine or ketamine on 
the dopaminergic system.  The high-affinity state of the D2 dopamine receptor (D2High) has been 
hypothesized to play a role in psychosis (Seeman et al., 2006).  Both memantine and ketamine 
demonstrate, with similar affinity, agonist actions at the D2High receptor (Seeman et al., 2005; 
Seeman et al., 2008).  Both drugs have also been shown to increase dopamine release in the 
cortex of rats (Verma and Moghaddam, 1996; Moghaddam et al., 1997; Hesselink et al., 1999; 
Lorrain et al., 2003).  While these actions on the dopaminergic system may contribute to the 
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similar behavioral and cognitive effects of these two drugs we measured in rats, they are unlikely 
to explain their different tolerability in humans.  
The serotonergic system is differentially affected by memantine and ketamine.  Ketamine 
is a much weaker antagonist at 5-HT3 serotonin receptors than memantine (Rammes et al., 2001; 
Kos et al., 2006).  It is possible that the differential actions of memantine and ketamine at 5-HT3 
receptors may affect the behavioral and cognitive effects of these drugs.  5-HT3 receptors are 
present in many brain regions thought to be involved in schizophrenia, including the cortex 
(Hagan et al., 1993).  5-HT3 antagonists can decrease hyperactivity of dopaminergic neurons 
(Faerber et al., 2007), an effect that should be beneficial in alleviating the symptoms of 
schizophrenia (Seeman, 2002; Stone et al., 2007).  Thus any psychotomimetic effects of 
memantine that result from its ability to increase dopamine release may be partially counteracted 
by inhibition of 5-HT3 receptors.  Ketamine’s similar ability to release dopamine, coupled with 
its weaker inhibition of 5-HT3 receptors, could result in stronger psychotomimetic effects.  
However, it should be mentioned that 5-HT3 receptor antagonists were not beneficial to 
schizophrenic individuals in clinical trials (Faerber et al., 2007).  Further research needs to 
address the actions of memantine and ketamine on neurotransmitter systems other than the 
glutamatergic system, and how effects on these systems may contribute to the varying 
tolerability reported for low doses of these drugs in humans.  Contributions of other 
neurotransmitter systems to the behavioral and cognitive deficits elicited by high doses of 
memantine and ketamine are even more likely, and should be examined as well. 
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5.5 CONCLUDING COMMENTS 
The findings reported in this document demonstrate the difficulties inherent in attempting to 
correlate basic research results into a comprehensive account of the actions exerted by a given 
drug in humans and other animals.  The simplification of a system to examine specific effects of 
a drug is an important, and as of yet, only way to gather a detailed understanding of a drug’s 
effects.  However, the physiological environment in which drugs are exerting their actions 
ultimately cannot be ignored and may profoundly alter their effects at a specific target.  Species 
related differences between animal models used for research and humans complicates the 
application of basic research findings to understanding of drug actions on human CNS 
functioning.  Species differences in drug distribution and metabolism will greatly affect the 
actions elicited by a given drug on the CNS functioning of the animal, as well as the resultant 
behavioral and cognitive effects.  For instance, rodent metabolism is much faster than human 
metabolism, resulting in faster elimination of a given drug dose from the rodent CNS than from 
the human CNS (Parsons et al., 2007).  Furthermore, the human cortex is much more highly 
developed than the rodent cortex (Robbins, 1998).  Differences in neurotransmitter receptor 
distribution and connections among the different neurotransmitter systems that are likely to exist 
across species makes comparisons of drug effects even more difficult.  Addressing these 
complications will likely further our ability to use findings gathered through diverse research 
techniques to increase our understanding of the human consequences of a drug’s action. 
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